foscarnet has been researched along with AIDS-Related Opportunistic Infections in 243 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
AIDS-Related Opportunistic Infections: Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The clinical significance of cytomegalovirus (CMV) foscarnet resistance was studied in patients with acquired immunodeficiency syndrome and CMV retinitis." | 9.10 | Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. ( Chou, S; Crumpacker, C; Forman, MS; Jabs, DA; Lurain, NS; Martin, BK; Weinberg, A, 2003) |
| "The efficacy and toxicity of foscarnet cream for the treatment of mucocutaneous herpes simplex virus lesions or lesions that were clinically unresponsive to systemic acyclovir treatment (median, 30." | 9.09 | Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: a phase I/II study. ( Bryson, Y; Grafford, K; Hardy, WD; Javaly, K; Kalayjian, R; Klein, T; Martin-Munley, S; Wohlfeiler, M, 1999) |
| "A randomized open-label phase 2 trial compared the virological and clinical effects on cytomegalovirus (CMV) infection of a 14-day course of intravenous foscarnet (100 mg/[kg x 12 h]) or no treatment in 42 HIV-infected patients with < 100 CD4 cells/mm3 and persistent asymptomatic CMV viremia." | 9.09 | Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. Agence National de Recherche du SIDA 023 Study Group. ( Aboulker, JP; Brun-Vézinet, F; Carrière, I; Fillet, AM; Gérard, L; Houhou, N; Leport, C; Ostinelli, J; Salmon-Céron, D; Vildé, JL, 1999) |
| "Patients with symptomatic gastrointestinal disease due to cytomegalovirus (CMV) were randomized to receive open-label ganciclovir (22) or foscarnet (26)." | 9.08 | Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison. ( Benhamou, Y; Blanshard, C; Dohin, E; Gazzard, BG; Katlama, C; Lernestedt, JO, 1995) |
| "The use of foscarnet and ganciclovir as a combination treatment for cytomegalovirus retinitis is increasing because of limitations associated with single agent therapy." | 9.08 | Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis. ( Aweeka, FT; Emrick, L; Gambertoglio, JG; Jacobson, MA; Jayewardene, A; Kramer, F; Lizak, P; Polsky, B; Tong, W; van der Horst, C, 1995) |
| "Neutropenia was more common in patients assigned to ganciclovir than to foscarnet (34% vs 14%; P = ." | 9.08 | Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. ( , 1995) |
| "Four intravenous dosages of foscarnet given for 10 days were compared with no therapy in persons with AIDS who had asymptomatic cytomegalovirus (CMV) viremia." | 9.08 | Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS. ( Acosta, EP; Balfour, HH; Boivin, G; Crumpacker, CS; Eaton, CA; Erice, A; Fletcher, CV; Henry, WK; Holm, MA; Martin-Munley, SS; Shepp, DH; Smith, SA, 1996) |
| "Although several uncontrolled studies have shown that the response rate to ganciclovir and foscarnet for all forms of cytomegalovirus (CMV) infection in immunocompromised patients is almost similar, to date, no controlled clinical trial has been specifically designed to compare these two agents in the treatment of CMV esophagitis." | 9.08 | Treatment of cytomegalovirus esophagitis in patients with acquired immune deficiency syndrome: a randomized controlled study of foscarnet versus ganciclovir. The Italian Cytomegalovirus Study Group. ( Bianchi Porro, G; Parente, F, 1998) |
| "AIDS patients with newly diagnosed cytomegalovirus (CMV) retinitis who had just completed a 14-day course of ganciclovir induction therapy were randomly assigned to an alternating or concurrent combination regimen of chronic ganciclovir-foscarnet therapy for CMV retinitis." | 9.07 | Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151. ( Bassiakos, Y; Geheb, H; Hooton, T; Jacobson, MA; Korvick, JA; Kramer, F; O'Donnell, JJ; Polsky, B; van der Horst, C; Walker, JD, 1994) |
| " The Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial is a multicenter, randomized, controlled, unmasked, clinical trial that compared ganciclovir and foscarnet as treatments for CMV retinitis in patients with AIDS." | 9.07 | Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. ( , 1994) |
| "The efficacy and tolerance of high dose intravitreal foscarnet for cytomegalovirus retinitis in patients with AIDS was studied." | 9.07 | High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS. ( Cano, J; Chipont, E; Diaz-Llopis, M; España, E; Menezo, JL; Muñoz, G; Navea, A; Romero, FJ, 1994) |
| "The aim of this study was to investigate peripheral blood polymorphonuclear leukocytes and, whenever possible, aqueous humor from 65 AIDS patients with ophthalmoscopically diagnosed human cytomegalovirus (HCMV) retinitis to determine (i) whether patients consistently carry viral DNA and (ii) to what extent foscarnet induction treatment decreases viral DNA levels." | 9.07 | Effect of foscarnet induction treatment on quantitation of human cytomegalovirus (HCMV) DNA in peripheral blood polymorphonuclear leukocytes and aqueous humor of AIDS patients with HCMV retinitis. The Italian Foscarnet Study Group. ( Baldanti, F; Furione, M; Gerna, G; Percivalle, E; Revello, MG; Sarasini, A; Zella, D; Zipeto, D, 1994) |
| "Thirty-two patients with AIDS and previously untreated cytomegalovirus retinitis completed an induction course of foscarnet, 60 mg/kg every 8 h for 14 days, had retinitis stabilize, and were then randomly assigned to receive foscarnet maintenance as either a 90- or 120-mg/kg/day infusion administered over 2 h." | 9.07 | A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. ( Causey, D; Chown, M; Davis, R; Hardy, D; Heinemann, MH; Holland, GN; Jacobson, MA; Kuppermann, BD; O'Donnell, JJ; Polsky, B, 1993) |
| "Acyclovir-resistant herpes simplex virus (HSV) infection is common in immunocompromised patients, but the course of such infection is little known." | 7.80 | Long-term follow-up of HIV-infected patients once diagnosed with acyclovir-resistant herpes simplex virus infection. ( Agut, H; Boutolleau, D; Burrel, S; Caumes, E; Epelboin, L; Katlama, C; Regnier, S; Seang, S; Valantin, MA; Voujon, D, 2014) |
| "To describe the chronic use of high doses of intravitreal ganciclovir, in combination with foscarnet, for the treatment of cytomegalovirus retinitis." | 7.71 | High-dose intravitreal ganciclovir and foscarnet for cytomegalovirus retinitis. ( Chan, CC; Robinson, MR; Roy, CE; Velez, G; Whitcup, SM, 2001) |
| "Sequential herpes simplex virus (HSV) isolates from AIDS patients receiving foscarnet therapy were evaluated for susceptibility to adefovir." | 7.71 | Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy. ( Bestman-Smith, J; Boivin, G, 2002) |
| "Three human immunodeficiency virus-infected subjects with progressive cytomegalovirus (CMV) retinitis despite prolonged antiviral therapy had buffy coat CMV isolates that were resistant to both ganciclovir and foscarnet." | 7.70 | Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. ( Chou, S; Drew, WL; Gordon, SM; LaVoy, AG; Marousek, G; Miner, RC; Parenti, DM; Ross, JG, 1998) |
| " In this report we describe the effects of foscarnet on HHV-8 viremia in an HIV-infected patient with disseminated Kaposi s sarcoma and a presumably HHV-8 associated hemophagocytic syndrome." | 7.70 | Suppression of HHV-8 viremia by foscarnet in an HIV-infected patient with Kaposi's sarcoma and HHV-8 associated hemophagocytic syndrome. ( Fleckenstein, B; Harrer, T; Kalden, JR; Löw, P; Manger, B; Neipel, F; Rascu, A; Steininger, H, 1998) |
| "Herpes simplex virus (HSV) isolates were characterized from 8 AIDS patients in whom acyclovir and foscarnet therapy sequentially failed." | 7.70 | Characterization of the DNA polymerase and thymidine kinase genesof herpes simplex virus isolates from AIDS patients in whom acyclovirand foscarnet therapy sequentially failed. ( Boivin, G; Schmit, I, 1999) |
| "We report on a 28-year-old AIDS patient who developed a rapidly progressive glomerulonephritis while being treated with foscarnet for cytomegalovirus retinitis." | 7.69 | Crescentic glomerulonephritis and crystals within glomerular capillaries in an AIDS patient treated with foscarnet. ( Cahen, R; Cotte, L; Dijoud, F; François, B; Patricot, LM; Trepo, C; Trolliet, P, 1995) |
| "Foscarnet-resistant cytomegalovirus (ID50 > 300 microM) was isolated from two patients, one of whom was being treated with foscarnet." | 7.69 | Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir. ( Apuzzo, L; Charache, P; Dunn, JP; Forman, MS; Jabs, DA; MacCumber, MW, 1995) |
| "CMV esophagitis has a favorable response to induction ganciclovir therapy, and a long-term remission may occur after induction therapy alone." | 7.69 | Cytomegalovirus esophagitis in AIDS: a prospective evaluation of clinical response to ganciclovir therapy, relapse rate, and long-term outcome. ( Schwartz, DA; Straub, RF; Wilcox, CM, 1995) |
| " One patient with AIDS suffered from a perineal lesion due to infection with herpes simplex virus type 2 (HSV-2) and did not respond to acyclovir and was intolerant of foscarnet." | 7.69 | Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). ( Andrei, G; Balzarini, J; Clumeck, N; De Clercq, E; Gérard, M; Hedderman, A; Sadzot-Delvaux, C; Silverman, A; Snoeck, R; Tricot, G, 1994) |
| "These results suggest that while ganciclovir therapy may clinically stabilize CMV retinitis in patients with AIDS, it does not appear to prevent the development of, or be effective in the treatment of, CMV encephalitis." | 7.69 | The development of cytomegalovirus encephalitis in AIDS patients receiving ganciclovir. ( Berman, SM; Kim, RC, 1994) |
| "We treated seven patients (nine eyes) who had cytomegalovirus retinitis with daily intravenous ganciclovir plus foscarnet." | 7.69 | Combined daily therapy with intravenous ganciclovir and foscarnet for patients with recurrent cytomegalovirus retinitis. ( Murphy, R; Naughton, K; Weinberg, DV, 1994) |
| "Four human cytomegalovirus (HCMV) isolates from four different AIDS patients treated with both ganciclovir and foscarnet and not responding clinically to antiviral treatment, were studied in order to verify the occurrence of double resistance to both drugs, and to define whether single or multiple HCMV strains could be responsible for the double resistance." | 7.69 | Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients. ( Baldanti, F; Barbi, M; Brerra, R; Furione, M; Gerna, G; Percivalle, E; Sarasini, A, 1995) |
| "Three human cytomegalovirus (HCMV) strains (VR4760, VR4955, and VR5120) showing double resistance to ganciclovir (GCV) and foscarnet (PFA) were isolated from three patients with AIDS who underwent multiple sequential courses of therapy with GCV and PFA (A." | 7.69 | Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered f ( Baldanti, F; Biron, KK; Chou, S; Gerna, G; Sarasini, A; Silini, E; Stanat, SC; Underwood, MR, 1996) |
| "To determine the efficacy of combined ganciclovir and foscarnet intravitreal injections in controlling clinically resistant cytomegalovirus retinitis in a 37-year-old man with the acquired immunodeficiency syndrome who refused systemic therapy." | 7.69 | Treatment of clinically resistant cytomegalovirus retinitis with combined intravitreal injections of ganciclovir and foscarnet. ( Desatnik, HR; Foster, RE; Lowder, CY, 1996) |
| "Four human cytomegalovirus strains with double resistance to both ganciclovir and foscarnet were recovered from acquired immunodeficiency syndrome (AIDS) patients." | 7.69 | Four dually resistant human cytomegalovirus strains from AIDS patients: single mutations in UL97 and UL54 open reading frames are responsible for ganciclovir- and foscarnet-specific resistance, respectively. ( Baldanti, F; Barbi, M; Biron, KK; Gerna, G; Lazzarin, A; Sarasini, A; Silini, E, 1995) |
| " Administration of foscarnet during two years, recommended as suppressive therapy for a previous cytomegalovirus retinitis, might have caused a sustained reduction in plasma HIV-RNA, contributing to her long-term survival." | 7.69 | [Long term survival in an HIV-immunosuppressed patient treated with foscarnet]. ( Bravo, R; González-Lahoz, J; Mas, A; Moreno, V; Soriano, V, 1996) |
| "To assess the clinical response and patient tolerance to daily infusions of both ganciclovir sodium and foscarnet sodium for the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome." | 7.68 | Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. ( Flores-Aguilar, M; Freeman, WR; Kuppermann, BD; Quiceno, JI; Rickman, LS, 1993) |
| "Foscarnet (phosphonoformate) is a potent virustatic drug against herpes-like viruses and is widely used in the therapy of cytomegalovirus infections in immunosuppressed patients." | 7.68 | Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis. ( Brockmeyer, NH; Goos, M; Hengge, UR; Malessa, R; Ravens, U, 1993) |
| " There was no difference between the 2 groups in either serious adverse events or rise of creatinine to > or = 2." | 6.69 | Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovirus infections. ( Benson, P; Cheung, TW; Jayaweera, DT; Nahass, R; Olson, C; Pearce, D; Wool, GM, 2000) |
| "Patients were randomized to one of three therapeutic regimens: induction with foscarnet sodium at 90 mg/kg intravenously every 12 hours for 2 weeks, followed by maintenance at a dosage of 120 mg/kg per day (foscarnet group); induction with ganciclovir sodium at 5 mg/kg intravenously every 12 hours for 2 weeks followed by maintenance at 10 mg/kg per day (ganciclovir group); or continuation of previous maintenance therapy plus induction with the other drug (either ganciclovir or foscarnet) for 2 weeks followed by maintenance therapy with both drugs, ganciclovir sodium at 5 mg/kg per day and foscarnet sodium at 90 mg/kg per day (combination therapy group)." | 6.68 | Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration ( , 1996) |
| "Retinal detachment was not associated with the type of anticytomegalovirus therapy (intravenous foscarnet or ganciclovir) to which the patient was assigned." | 6.68 | Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: the Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS (SOCA) Research Group in Collaboration with the AIDS Clinical Trials Group ( , 1997) |
| " In both regimens the elimination half-life of foscarnet was 2-3 h." | 6.68 | Comparison of pharmacokinetics and dynamics of two dosage regimens of foscarnet in AIDS patients with Cytomegalovirus retinitis. ( Carosi, G; Castelli, F; Hedman, A; Suter, F; Tomasoni, L; Trespi, G; Zeroli, C, 1997) |
| "The DNA polymerase of human herpes viruses, including cytomegalovirus (CMV), and the reverse transcriptase of human immunodeficiency virus (HIV) are selectively inhibited in vitro by the pyrophosphate analogue foscarnet." | 6.17 | Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. ( Bryson, HM; Wagstaff, AJ, 1994) |
| "A 41-year-old man with acquired immunodeficiency syndrome (AIDS) developed cytomegalovirus (CMV) retinitis." | 5.29 | [Foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome]. ( Fujino, Y; Kimura, S; Mochizuki, M; Mouri, H; Nagata, Y; Oka, S; Ono, A; Shimada, K, 1994) |
| " The dosing regimen for induction with the combined therapy was foscarnet (60 mg/kg every 8 hours) and ganciclovir (5 mg/kg daily for 3 weeks)." | 5.29 | Combined intravenous ganciclovir and foscarnet for children with recurrent cytomegalovirus retinitis. ( Lewis, LL; Mueller, BU; Nussenblatt, RB; Pizzo, PA; Walton, RC; Whitcup, SM, 1995) |
| "After withdrawal from maintenance treatment, a relapse of cytomegalovirus retinitis occurred, which was again successfully treated with ganciclovir." | 5.28 | 2.5 years survival with sequential ganciclovir/foscarnet treatment in a patient with acquired immune deficiency syndrome and cytomegalovirus retinitis. ( Geier, SA; Goebel, FD; Klauss, V; Kronawitter, U; Matuschke, A, 1992) |
| "The clinical significance of cytomegalovirus (CMV) foscarnet resistance was studied in patients with acquired immunodeficiency syndrome and CMV retinitis." | 5.10 | Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. ( Chou, S; Crumpacker, C; Forman, MS; Jabs, DA; Lurain, NS; Martin, BK; Weinberg, A, 2003) |
| "The efficacy and toxicity of foscarnet cream for the treatment of mucocutaneous herpes simplex virus lesions or lesions that were clinically unresponsive to systemic acyclovir treatment (median, 30." | 5.09 | Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: a phase I/II study. ( Bryson, Y; Grafford, K; Hardy, WD; Javaly, K; Kalayjian, R; Klein, T; Martin-Munley, S; Wohlfeiler, M, 1999) |
| "To evaluate the efficacy and safety of the foscarnet-ganciclovir combination in induction therapy (IT) and maintenance therapy (MT) for cytomegalovirus (CMV) central neurological disorders in HIV-infected patients." | 5.09 | Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients. ( Anduze-Faris, BM; Boukli, N; Caumes, E; Costagliola, D; Fillet, AM; Gasnault, J; Gozlan, J; Katlama, C; Lancar, R; Leport, C; Livartowsky, J; Matheron, S; Salmon, D, 2000) |
| "A randomized open-label phase 2 trial compared the virological and clinical effects on cytomegalovirus (CMV) infection of a 14-day course of intravenous foscarnet (100 mg/[kg x 12 h]) or no treatment in 42 HIV-infected patients with < 100 CD4 cells/mm3 and persistent asymptomatic CMV viremia." | 5.09 | Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. Agence National de Recherche du SIDA 023 Study Group. ( Aboulker, JP; Brun-Vézinet, F; Carrière, I; Fillet, AM; Gérard, L; Houhou, N; Leport, C; Ostinelli, J; Salmon-Céron, D; Vildé, JL, 1999) |
| "Patients with symptomatic gastrointestinal disease due to cytomegalovirus (CMV) were randomized to receive open-label ganciclovir (22) or foscarnet (26)." | 5.08 | Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison. ( Benhamou, Y; Blanshard, C; Dohin, E; Gazzard, BG; Katlama, C; Lernestedt, JO, 1995) |
| "The use of foscarnet and ganciclovir as a combination treatment for cytomegalovirus retinitis is increasing because of limitations associated with single agent therapy." | 5.08 | Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis. ( Aweeka, FT; Emrick, L; Gambertoglio, JG; Jacobson, MA; Jayewardene, A; Kramer, F; Lizak, P; Polsky, B; Tong, W; van der Horst, C, 1995) |
| "Foscarnet inhibits human immunodeficiency virus (HIV) replication in vitro and decreases p24 antigenemia in patients with cytomegalovirus (CMV) retinitis." | 5.08 | Foscarnet decreases human immunodeficiency virus RNA. ( Furrer, H; Hirschel, B; Kaiser, L; Olmari, M; Perrin, L; Von Overbeck, J; Yerly, S, 1995) |
| "Neutropenia was more common in patients assigned to ganciclovir than to foscarnet (34% vs 14%; P = ." | 5.08 | Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. ( , 1995) |
| "Twenty-six subjects enrolled in a randomized trial that compared foscarnet and ganciclovir for the treatment of cytomegalovirus retinitis." | 5.08 | Measuring visual function and quality of life in patients with cytomegalovirus retinitis. Development of a questionnaire. Studies of Ocular Complication of AIDS Research Group. ( Coleson, LC; Holbrook, J; Jabs, DA; Wu, AW, 1996) |
| "Four intravenous dosages of foscarnet given for 10 days were compared with no therapy in persons with AIDS who had asymptomatic cytomegalovirus (CMV) viremia." | 5.08 | Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS. ( Acosta, EP; Balfour, HH; Boivin, G; Crumpacker, CS; Eaton, CA; Erice, A; Fletcher, CV; Henry, WK; Holm, MA; Martin-Munley, SS; Shepp, DH; Smith, SA, 1996) |
| "Although several uncontrolled studies have shown that the response rate to ganciclovir and foscarnet for all forms of cytomegalovirus (CMV) infection in immunocompromised patients is almost similar, to date, no controlled clinical trial has been specifically designed to compare these two agents in the treatment of CMV esophagitis." | 5.08 | Treatment of cytomegalovirus esophagitis in patients with acquired immune deficiency syndrome: a randomized controlled study of foscarnet versus ganciclovir. The Italian Cytomegalovirus Study Group. ( Bianchi Porro, G; Parente, F, 1998) |
| "To evaluate the efficacy of ganciclovir, foscarnet, or the combination of both for the treatment of cytomegalovirus polyradiculomyelopathy (CMV-PRAM), we reviewed the records of seven patients with AIDS, diagnosed with CMV-PRAM." | 5.08 | [Cytomegalovirus polyradiculomyelopathy in AIDS]. ( Cassetti, LI; Espinoza, L; Hansman-Whiteman, ML; Jayaweera, DT; Lopardo, GD; Scerpella, EG, 1998) |
| "AIDS patients with newly diagnosed cytomegalovirus (CMV) retinitis who had just completed a 14-day course of ganciclovir induction therapy were randomly assigned to an alternating or concurrent combination regimen of chronic ganciclovir-foscarnet therapy for CMV retinitis." | 5.07 | Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151. ( Bassiakos, Y; Geheb, H; Hooton, T; Jacobson, MA; Korvick, JA; Kramer, F; O'Donnell, JJ; Polsky, B; van der Horst, C; Walker, JD, 1994) |
| " The Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial is a multicenter, randomized, controlled, unmasked, clinical trial that compared ganciclovir and foscarnet as treatments for CMV retinitis in patients with AIDS." | 5.07 | Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. ( , 1994) |
| "The efficacy and tolerance of high dose intravitreal foscarnet for cytomegalovirus retinitis in patients with AIDS was studied." | 5.07 | High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS. ( Cano, J; Chipont, E; Diaz-Llopis, M; España, E; Menezo, JL; Muñoz, G; Navea, A; Romero, FJ, 1994) |
| "The aim of this study was to investigate peripheral blood polymorphonuclear leukocytes and, whenever possible, aqueous humor from 65 AIDS patients with ophthalmoscopically diagnosed human cytomegalovirus (HCMV) retinitis to determine (i) whether patients consistently carry viral DNA and (ii) to what extent foscarnet induction treatment decreases viral DNA levels." | 5.07 | Effect of foscarnet induction treatment on quantitation of human cytomegalovirus (HCMV) DNA in peripheral blood polymorphonuclear leukocytes and aqueous humor of AIDS patients with HCMV retinitis. The Italian Foscarnet Study Group. ( Baldanti, F; Furione, M; Gerna, G; Percivalle, E; Revello, MG; Sarasini, A; Zella, D; Zipeto, D, 1994) |
| "Thirty-two patients with AIDS and previously untreated cytomegalovirus retinitis completed an induction course of foscarnet, 60 mg/kg every 8 h for 14 days, had retinitis stabilize, and were then randomly assigned to receive foscarnet maintenance as either a 90- or 120-mg/kg/day infusion administered over 2 h." | 5.07 | A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. ( Causey, D; Chown, M; Davis, R; Hardy, D; Heinemann, MH; Holland, GN; Jacobson, MA; Kuppermann, BD; O'Donnell, JJ; Polsky, B, 1993) |
| " Herpes virus type 1 and rarely type 2 may lead to painful and resistant oral ulcers, and systemic treatment with acyclovir, valaciclovir or famciclovir is indicated." | 4.79 | Viral lesions of the mouth in HIV-infected patients. ( Itin, PH; Lautenschlager, S, 1997) |
| "The nucleoside analog acyclovir is remarkably effective and selective in herpes simplex virus (HSF) infections." | 4.78 | [Resistance of herpes simplex viruses to antiviral drugs]. ( Bianchi, A; Scieux, C, 1993) |
| "Acyclovir-resistant herpes simplex virus (HSV) infection is common in immunocompromised patients, but the course of such infection is little known." | 3.80 | Long-term follow-up of HIV-infected patients once diagnosed with acyclovir-resistant herpes simplex virus infection. ( Agut, H; Boutolleau, D; Burrel, S; Caumes, E; Epelboin, L; Katlama, C; Regnier, S; Seang, S; Valantin, MA; Voujon, D, 2014) |
| "To describe the chronic use of high doses of intravitreal ganciclovir, in combination with foscarnet, for the treatment of cytomegalovirus retinitis." | 3.71 | High-dose intravitreal ganciclovir and foscarnet for cytomegalovirus retinitis. ( Chan, CC; Robinson, MR; Roy, CE; Velez, G; Whitcup, SM, 2001) |
| "To determine the prevalence of the in vitro resistance rate of cytomegalovirus (CMV) to gancyclovir (GCV) and foscarnet (FOS) among patients with AIDS and chorioretinitis." | 3.71 | [Cytomegalovirus sensitivity to anti-retroviral agents in patients infected with the human immunodeficiency virus with chorioretinitis in Spain]. ( Cañizares, MA; Casado, JL; González, J; Guerrero, A; Losada, I; Pérez-Elías, MJ; Rubio, R, 2001) |
| "Sequential herpes simplex virus (HSV) isolates from AIDS patients receiving foscarnet therapy were evaluated for susceptibility to adefovir." | 3.71 | Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy. ( Bestman-Smith, J; Boivin, G, 2002) |
| "Three human immunodeficiency virus-infected subjects with progressive cytomegalovirus (CMV) retinitis despite prolonged antiviral therapy had buffy coat CMV isolates that were resistant to both ganciclovir and foscarnet." | 3.70 | Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. ( Chou, S; Drew, WL; Gordon, SM; LaVoy, AG; Marousek, G; Miner, RC; Parenti, DM; Ross, JG, 1998) |
| "Three acquired immune deficiency syndrome patients given foscarnet to treat cytomegalovirus retinitis developed renal failure with crystal deposits within the renal glomeruli." | 3.70 | Identification of crystals in kidneys of AIDS patients treated with foscarnet. ( Beaufils, H; Daudon, M; Jouanneau, C; Katlama, C; Lacour, B; Maurice-Estepa, L; Sazdovitch, V, 1998) |
| " In this report we describe the effects of foscarnet on HHV-8 viremia in an HIV-infected patient with disseminated Kaposi s sarcoma and a presumably HHV-8 associated hemophagocytic syndrome." | 3.70 | Suppression of HHV-8 viremia by foscarnet in an HIV-infected patient with Kaposi's sarcoma and HHV-8 associated hemophagocytic syndrome. ( Fleckenstein, B; Harrer, T; Kalden, JR; Löw, P; Manger, B; Neipel, F; Rascu, A; Steininger, H, 1998) |
| "Herpes simplex virus (HSV) isolates were characterized from 8 AIDS patients in whom acyclovir and foscarnet therapy sequentially failed." | 3.70 | Characterization of the DNA polymerase and thymidine kinase genesof herpes simplex virus isolates from AIDS patients in whom acyclovirand foscarnet therapy sequentially failed. ( Boivin, G; Schmit, I, 1999) |
| "We report on a 28-year-old AIDS patient who developed a rapidly progressive glomerulonephritis while being treated with foscarnet for cytomegalovirus retinitis." | 3.69 | Crescentic glomerulonephritis and crystals within glomerular capillaries in an AIDS patient treated with foscarnet. ( Cahen, R; Cotte, L; Dijoud, F; François, B; Patricot, LM; Trepo, C; Trolliet, P, 1995) |
| " We attempted to detect cytomegalovirus DNA in 19 vitreous samples from patients with the acquired immunodeficiency syndrome (AIDS) who had untreated cytomegalovirus retinitis and in 40 vitreous samples from patients with AIDS who had been treated with systemic ganciclovir or foscarnet, or both." | 3.69 | A sensitive and specific polymerase chain reaction-based assay for the diagnosis of cytomegalovirus retinitis. ( Ai, E; Irvine, AR; Kuppermann, BD; Luckie, AP; Margolis, TP; McCann, JD; Schwartz, DM; Wong, MG, 1995) |
| "Foscarnet-resistant cytomegalovirus (ID50 > 300 microM) was isolated from two patients, one of whom was being treated with foscarnet." | 3.69 | Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir. ( Apuzzo, L; Charache, P; Dunn, JP; Forman, MS; Jabs, DA; MacCumber, MW, 1995) |
| "CMV esophagitis has a favorable response to induction ganciclovir therapy, and a long-term remission may occur after induction therapy alone." | 3.69 | Cytomegalovirus esophagitis in AIDS: a prospective evaluation of clinical response to ganciclovir therapy, relapse rate, and long-term outcome. ( Schwartz, DA; Straub, RF; Wilcox, CM, 1995) |
| " One patient with AIDS suffered from a perineal lesion due to infection with herpes simplex virus type 2 (HSV-2) and did not respond to acyclovir and was intolerant of foscarnet." | 3.69 | Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). ( Andrei, G; Balzarini, J; Clumeck, N; De Clercq, E; Gérard, M; Hedderman, A; Sadzot-Delvaux, C; Silverman, A; Snoeck, R; Tricot, G, 1994) |
| "These results suggest that while ganciclovir therapy may clinically stabilize CMV retinitis in patients with AIDS, it does not appear to prevent the development of, or be effective in the treatment of, CMV encephalitis." | 3.69 | The development of cytomegalovirus encephalitis in AIDS patients receiving ganciclovir. ( Berman, SM; Kim, RC, 1994) |
| "We treated seven patients (nine eyes) who had cytomegalovirus retinitis with daily intravenous ganciclovir plus foscarnet." | 3.69 | Combined daily therapy with intravenous ganciclovir and foscarnet for patients with recurrent cytomegalovirus retinitis. ( Murphy, R; Naughton, K; Weinberg, DV, 1994) |
| "Four human cytomegalovirus (HCMV) isolates from four different AIDS patients treated with both ganciclovir and foscarnet and not responding clinically to antiviral treatment, were studied in order to verify the occurrence of double resistance to both drugs, and to define whether single or multiple HCMV strains could be responsible for the double resistance." | 3.69 | Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients. ( Baldanti, F; Barbi, M; Brerra, R; Furione, M; Gerna, G; Percivalle, E; Sarasini, A, 1995) |
| "Three human cytomegalovirus (HCMV) strains (VR4760, VR4955, and VR5120) showing double resistance to ganciclovir (GCV) and foscarnet (PFA) were isolated from three patients with AIDS who underwent multiple sequential courses of therapy with GCV and PFA (A." | 3.69 | Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered f ( Baldanti, F; Biron, KK; Chou, S; Gerna, G; Sarasini, A; Silini, E; Stanat, SC; Underwood, MR, 1996) |
| "To determine the efficacy of combined ganciclovir and foscarnet intravitreal injections in controlling clinically resistant cytomegalovirus retinitis in a 37-year-old man with the acquired immunodeficiency syndrome who refused systemic therapy." | 3.69 | Treatment of clinically resistant cytomegalovirus retinitis with combined intravitreal injections of ganciclovir and foscarnet. ( Desatnik, HR; Foster, RE; Lowder, CY, 1996) |
| "To determine the prevalence of cytomegalovirus (CMV) isolates resistant to ganciclovir sodium or foscarnet sodium at the time of diagnosis of CMV retinitis, prior to the initiation of therapy." | 3.69 | Cytomegalovirus retinitis and viral resistance. Prevalence of resistance at diagnosis, 1994. Cytomegalovirus Retinitis and Viral Resistance Study Group. ( Bressler, N; Charache, P; Dunn, JP; Enger, C; Forman, M; Jabs, DA, 1996) |
| "Four human cytomegalovirus strains with double resistance to both ganciclovir and foscarnet were recovered from acquired immunodeficiency syndrome (AIDS) patients." | 3.69 | Four dually resistant human cytomegalovirus strains from AIDS patients: single mutations in UL97 and UL54 open reading frames are responsible for ganciclovir- and foscarnet-specific resistance, respectively. ( Baldanti, F; Barbi, M; Biron, KK; Gerna, G; Lazzarin, A; Sarasini, A; Silini, E, 1995) |
| "We describe a 28-year-old HIV-infected woman with AIDS, defined by cerebral toxoplasmosis and a CD4-count of less than 10 x 10(6) cells/I, who, after several eruptions of genital herpes and typical dermatomal herpes zoster, all successfully treated with acyclovir, developed chronic cutaneous ulcerating lesions on a finger and on the tibia." | 3.69 | Chronic ulcerating acyclovir-resistant varicella zoster lesions in an AIDS patient. ( Bernhard, P; Obel, N, 1995) |
| " Administration of foscarnet during two years, recommended as suppressive therapy for a previous cytomegalovirus retinitis, might have caused a sustained reduction in plasma HIV-RNA, contributing to her long-term survival." | 3.69 | [Long term survival in an HIV-immunosuppressed patient treated with foscarnet]. ( Bravo, R; González-Lahoz, J; Mas, A; Moreno, V; Soriano, V, 1996) |
| "Antiviral susceptibilities to ganciclovir, foscarnet, and cidofovir and sequencing of UL97 and DNA polymerase were done on 23 cytomegalovirus (CMV) isolates from 10 immunocompromised persons with end-organ CMV disease who were treated with ganciclovir alone or ganciclovir followed by foscarnet." | 3.69 | Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. ( Balfour, HH; Boivin, G; Chou, S; Erice, A; Gil-Roda, C; Hanson, MN; Pérez, JL; Sannerud, KJ, 1997) |
| "In a human immunodeficiency virus-infected subject, cytomegalovirus (CMV) isolated 9 months after the patient began oral ganciclovir prophylaxis was resistant to ganciclovir and cidofovir and contained mutations in both UL97 and Pol coding regions." | 3.69 | Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. ( Chou, S; Drew, WL; Follansbee, SE; Guentzel, S; Lalezari, JP; Marousek, G; Miner, RC; Poscher, ME, 1997) |
| "In order to assess the value of quantitative measurement of cytomegalovirus (CMV) antigenaemia as a marker for the guidance of antiviral chemotherapy in the AIDS setting, 33 patients with CMV complications and showing at least 20 pp65-positive polymorphonuclear leucocytes per 2 x 10(5) cells, received either ganciclovir or foscarnet as induction and maintenance therapy." | 3.69 | Quantitative cytomegalovirus (CMV) antigenaemia during antiviral treatment of AIDS-related CMV disease. ( Chiodo, F; Coronado, OV; Dal Monte, P; Lazzarotto, T; Manfredi, R; Mastroianni, A; Spezzacatena, P, 1997) |
| ") are discussed, as is the use of imiquimod treatment for genital warts." | 3.69 | International Congress on Chemotherapy. ( Smart, T, 1995) |
| "Foscavir (foscarnet sodium) has been approved by the Food and Drug Administration (FDA) for use in combination with Cytovene (intravenous ganciclovir) for the treatment of recurrent AIDS-related cytomegalovirus retinitis that has been treated previously with either drug alone." | 3.69 | Foscavir receives new indication. ( , 1997) |
| "To assess the clinical response and patient tolerance to daily infusions of both ganciclovir sodium and foscarnet sodium for the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome." | 3.68 | Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. ( Flores-Aguilar, M; Freeman, WR; Kuppermann, BD; Quiceno, JI; Rickman, LS, 1993) |
| "Foscarnet (phosphonoformate) is a potent virustatic drug against herpes-like viruses and is widely used in the therapy of cytomegalovirus infections in immunosuppressed patients." | 3.68 | Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis. ( Brockmeyer, NH; Goos, M; Hengge, UR; Malessa, R; Ravens, U, 1993) |
| "Sequential visual field testing is an extremely helpful adjunct to ophthalmoscopy and fundus photography in the management of cytomegalovirus (CMV) retinitis with the antiviral agents ganciclovir or foscarnet in patients with the acquired immune deficiency syndrome (AIDS)." | 3.68 | Visual field testing in the management of cytomegalovirus retinitis. ( Bachman, DM; Bruni, LM; DiGioia, RA; Harris, PJ; McMackin, CM; Pistole, MC; Thomas, RM; Ward, DJ, 1992) |
| "ACTG 266 was designed as a randomized study to evaluate two doses of the human monoclonal antibody directed against CMV gH (MSL-109) versus placebo, each in combination with standard antiviral therapy for the treatment of newly diagnosed Cytomegalovirus (CMV) retinitis in AIDS patients." | 2.71 | A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus re ( Alston, B; Asmuth, DM; Aweeka, F; Borucki, MJ; Caliendo, A; Gnann, J; Hirsch, MS; Hubbard, L; Nadler, PI; Nevin, TT; Nokta, M; Owens, S; Pollard, RB; Sattler, F; Spritzler, J; Waterman, K, 2004) |
| " There was no difference between the 2 groups in either serious adverse events or rise of creatinine to > or = 2." | 2.69 | Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovirus infections. ( Benson, P; Cheung, TW; Jayaweera, DT; Nahass, R; Olson, C; Pearce, D; Wool, GM, 2000) |
| "Patients were randomized to one of three therapeutic regimens: induction with foscarnet sodium at 90 mg/kg intravenously every 12 hours for 2 weeks, followed by maintenance at a dosage of 120 mg/kg per day (foscarnet group); induction with ganciclovir sodium at 5 mg/kg intravenously every 12 hours for 2 weeks followed by maintenance at 10 mg/kg per day (ganciclovir group); or continuation of previous maintenance therapy plus induction with the other drug (either ganciclovir or foscarnet) for 2 weeks followed by maintenance therapy with both drugs, ganciclovir sodium at 5 mg/kg per day and foscarnet sodium at 90 mg/kg per day (combination therapy group)." | 2.68 | Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration ( , 1996) |
| " Adverse events resulted in discontinuance of medication in the case of one patient." | 2.68 | Treatment of gastrointestinal cytomegalovirus infection with twice-daily foscarnet: a pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS. ( Dieterich, DT; Faust, MJ; Johnson, J; Lew, EA; Martin-Munley, S; Nix, D; Poles, MA, 1997) |
| "Retinal detachment was not associated with the type of anticytomegalovirus therapy (intravenous foscarnet or ganciclovir) to which the patient was assigned." | 2.68 | Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: the Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS (SOCA) Research Group in Collaboration with the AIDS Clinical Trials Group ( , 1997) |
| " In both regimens the elimination half-life of foscarnet was 2-3 h." | 2.68 | Comparison of pharmacokinetics and dynamics of two dosage regimens of foscarnet in AIDS patients with Cytomegalovirus retinitis. ( Carosi, G; Castelli, F; Hedman, A; Suter, F; Tomasoni, L; Trespi, G; Zeroli, C, 1997) |
| "There are no published data on varicella in HIV-infected adults, however, probably because most adults have already experienced varicella prior to HIV infection." | 2.41 | Prevention and treatment of VZV infections in patients with HIV. ( Gershon, AA, 2001) |
| "The first is the acute retinal necrosis syndrome, which also may be seen in immunocompetent hosts." | 2.41 | Aseptic meningitis and optic neuritis preceding varicella-zoster progressive outer retinal necrosis in a patient with AIDS. ( Bellehemeur, T; DiazGranados, C; Franco-Paredes, C; Merchant, A; Rimland, D; Sanghi, P, 2002) |
| " New modes of treatment have attempted to prolong intervals between dosing and reduce drug-related toxicity in an effort to improve quality of life." | 2.40 | Pharmacologic management of cytomegalovirus retinitis: review of current and future therapeutic modalities. ( Bright, DC, 1997) |
| " Their adverse effects mostly involve bone marrow depression (e." | 2.39 | Adverse effects and drug interactions of clinical importance with antiviral drugs. ( Morris, DJ, 1994) |
| "The median number of recurrences up to the observation of foveal-sparing retinitis was two (range one to eight), and five patients had active CMV retinitis despite treatment for at least two continuous months." | 2.39 | A foveal-sparing pattern of cytomegalovirus retinitis in the acquired immunodeficiency syndrome. ( Ai, E; Luckie, AP, 1996) |
| "The incidence of cytomegalovirus retinitis has decreased significantly since the advent of antiretroviral therapy." | 1.40 | Management of ganciclovir-resistant cytomegalovirus retinitis in HIV infection in the era of antiretroviral therapy. ( Acheson, RW; Adler, H; Brannigan, ET; De Gascun, CF; Duffy, M; Keegan, DJ; Lambert, JS; McSweeney, F, 2014) |
| "The foscarnet resistance was associated with an S725G mutation in a conserved region (region II) of the herpesvirus DNA pol gene." | 1.31 | Novel mutations in the thymidine kinase and DNA polymerase genes of acyclovir and foscarnet resistant herpes simplex viruses infecting an immunocompromised patient. ( Birch, C; Chibo, D; Doherty, R; Mijch, A, 2002) |
| "In one eye, the cystoid macular edema was worsened by formation of a dense juxtafoveal epiretinal membrane." | 1.30 | Cystoid macular edema associated with cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. ( Cunningham, ET; Jones, MR; Schwartz, D; Silverstein, BE; Smith, JH; Sykes, SO, 1998) |
| "A mild recurrence developed in one eye when ganciclovir and foscarnet were both tapered to a single daily dose." | 1.30 | The progressive outer retinal necrosis syndrome: successful treatment with combination antiviral therapy. ( Ciulla, TA; Duker, JS; Morley, MG; Rutledge, BK, 1998) |
| "The initial and maintenance treatment of CMV retinitis must be individualized based on the characteristics of the lesions, including location and extent, specific patient factors, and characteristics of available therapies among others." | 1.30 | Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA. ( Benson, CA; Deutsch, TA; Dieterich, DT; Drew, WL; Feinberg, J; Friedberg, DN; Griffiths, PD; Hardy, WD; Holland, GN; Jabs, DA; Jacobson, MA; Kessler, HA; Polis, MA; Powderly, WG; Spector, SA; Walmsley, S; Whitley, RJ, 1998) |
| "The acute lumbosacral polyradiculomyelitis (ALP) in patients with AIDS is a well defined nosologic entity and classically associated to CMV infection." | 1.30 | [Lumbosacral polyradiculomyelitis caused by herpes simplex virus (HSV) in a patient with AIDS]. ( Correa-Nazco, VJ; González, M; Laynez, P; Linares, M; Martínez, A; Miguélez, M, 1999) |
| "CMV viremia was present in 4 patients." | 1.29 | Cytomegalovirus ventriculoencephalitis in AIDS patients. ( Fernandez-Viladrich, P; Ferrer, I; Gudiol, F; Perez, JL; Podzamczer, D; Reñe, R; Salazar, A; Santin, M, 1995) |
| "Among the 861 patients with AIDS treated in our unit from 1991 to 1993, 7 cases involving cytomegalovirus infection of the conus medullaris and/or the cauda equina were studied retrospectively." | 1.29 | [Lesions of the conus medullaris and the cauda equina caused by cytomegalovirus in HIV infection. 7 cases]. ( el Amrani, M; Girard, PM; Gozlan, J; Jacomet, C; Lebrette, MG; Monfort, L; Rozenbaum, W, 1995) |
| "A 41-year-old man with acquired immunodeficiency syndrome (AIDS) developed cytomegalovirus (CMV) retinitis." | 1.29 | [Foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome]. ( Fujino, Y; Kimura, S; Mochizuki, M; Mouri, H; Nagata, Y; Oka, S; Ono, A; Shimada, K, 1994) |
| "Retinal detachment was seen in 14 patients (relative frequency, 19." | 1.29 | Retinal detachment in patients with acquired immunodeficiency syndrome. ( Bogner, JR; Geier, SA; Goebel, FD; Klauss, V; Sadri, I; Schmidt-Kittler, H, 1994) |
| "In four of the five patients, recurrences were temporally associated with a reduction in the amount of antiviral medication being received." | 1.29 | Recurrence of presumed varicella-zoster virus retinopathy in patients with acquired immunodeficiency syndrome. ( Engstrom, RE; Holland, GN; Johnston, WH; Rimmer, S, 1993) |
| "Furthermore, this patient had sclerosing cholangitis of the intra- and extrahepatic bile ducts as well as papillary stenosis." | 1.29 | Acalculous cholecystitis associated with cytomegalovirus and sclerosing cholangitis in a patient with acquired immunodeficiency syndrome. ( Baron, DL; Brunton, JL; Gallinger, S; Keshavjee, SH; Magee, LA; Mullen, BJ, 1993) |
| "Effective diagnosis and treatment of cytomegalovirus infection of the nervous system in AIDS patients has been limited by a lack of sensitive diagnostic measures." | 1.29 | Prognosis and response to therapy of cytomegalovirus encephalitis and meningomyelitis in AIDS. ( Cohen, BA, 1996) |
| "Among the atypical forms of chronic varicella, this eruption appears to be unique." | 1.29 | Chronic varicella presenting as disseminated pinpoint-sized papules in a man infected with the human immunodeficiency virus. ( Castanet, J; Durant, J; Lacour, JP; Ortonne, JP; Perrin, C; Rodot, S; Van Elslande, L, 1996) |
| " The dosing regimen for induction with the combined therapy was foscarnet (60 mg/kg every 8 hours) and ganciclovir (5 mg/kg daily for 3 weeks)." | 1.29 | Combined intravenous ganciclovir and foscarnet for children with recurrent cytomegalovirus retinitis. ( Lewis, LL; Mueller, BU; Nussenblatt, RB; Pizzo, PA; Walton, RC; Whitcup, SM, 1995) |
| "The P & T Committee at Trinity Lutheran Hospital, a 320-bed, community/teaching hospital in Kansas City, MO, has developed dosing and monitoring guidelines for foscarnet sodium (Foscavir) and trimetrexate glucuronate (Neutrexin)--two drugs used to treat patients with opportunistic infections associated with the human immunodeficiency virus (HIV)." | 1.29 | Dosing guidelines for foscarnet and trimetrexate. ( Chase, K; Henry, RB; O'Connor, MC; Wooten, JM, 1995) |
| "After withdrawal from maintenance treatment, a relapse of cytomegalovirus retinitis occurred, which was again successfully treated with ganciclovir." | 1.28 | 2.5 years survival with sequential ganciclovir/foscarnet treatment in a patient with acquired immune deficiency syndrome and cytomegalovirus retinitis. ( Geier, SA; Goebel, FD; Klauss, V; Kronawitter, U; Matuschke, A, 1992) |
| "Forty-four percent remained free of recurrences until they died (for up to 15 months); 56% had 1 to 4 recurrences, altogether 35 episodes, of which 14 occurred after withdrawal of therapy." | 1.28 | [Cytomegalovirus retinitis in AIDS. Effectiveness and complications of long-term therapy]. ( Fabricius, EM; Popescu, M; Schmitz, K, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 205 (84.36) | 18.2507 |
| 2000's | 32 (13.17) | 29.6817 |
| 2010's | 6 (2.47) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adler, H | 1 |
| De Gascun, CF | 1 |
| McSweeney, F | 1 |
| Acheson, RW | 1 |
| Brannigan, ET | 1 |
| Duffy, M | 1 |
| Keegan, DJ | 1 |
| Lambert, JS | 1 |
| Seang, S | 1 |
| Boutolleau, D | 1 |
| Burrel, S | 1 |
| Regnier, S | 1 |
| Epelboin, L | 1 |
| Voujon, D | 1 |
| Valantin, MA | 1 |
| Katlama, C | 7 |
| Agut, H | 2 |
| Caumes, E | 4 |
| Churgin, D | 1 |
| Relhan, N | 1 |
| Davis, JL | 2 |
| Albini, TA | 1 |
| Timperley, A | 1 |
| Taha, H | 1 |
| Das, S | 1 |
| Yudin, MH | 1 |
| Kaul, R | 1 |
| Sohal, A | 1 |
| Riordan, A | 1 |
| Mallewa, M | 1 |
| Solomon, T | 1 |
| Kneen, R | 1 |
| Jabs, DA | 12 |
| Martin, BK | 3 |
| Forman, MS | 3 |
| Di Lucca-Christment, J | 1 |
| Jacobelli, S | 1 |
| Gressier, L | 1 |
| Plantier, F | 1 |
| Laude, H | 1 |
| Rozenberg, F | 1 |
| Rosenberg, F | 1 |
| Morini, JP | 1 |
| Dallot, A | 1 |
| Avril, MF | 1 |
| Dupin, N | 1 |
| Kimberlin, DW | 1 |
| Scott, IU | 1 |
| Luu, KM | 1 |
| Chibo, D | 1 |
| Mijch, A | 1 |
| Doherty, R | 1 |
| Birch, C | 1 |
| Leśnikowski, ZJ | 1 |
| Paradowska, E | 1 |
| Przepiórkiewicz, M | 1 |
| Olejniczak, A | 1 |
| Emery, VC | 1 |
| Holbrook, JT | 3 |
| Weinberg, DV | 4 |
| Lewis, RA | 1 |
| Davis, MD | 2 |
| Friedberg, D | 1 |
| Weinberg, A | 1 |
| Chou, S | 5 |
| Lurain, NS | 1 |
| Crumpacker, C | 1 |
| Rapp, P | 1 |
| Pilon, F | 1 |
| Chiambaretta, F | 1 |
| Ménérath, JM | 1 |
| Jacomet, C | 2 |
| Borucki, MJ | 1 |
| Spritzler, J | 1 |
| Asmuth, DM | 1 |
| Gnann, J | 1 |
| Hirsch, MS | 1 |
| Nokta, M | 1 |
| Aweeka, F | 1 |
| Nadler, PI | 1 |
| Sattler, F | 1 |
| Alston, B | 1 |
| Nevin, TT | 1 |
| Owens, S | 2 |
| Waterman, K | 1 |
| Hubbard, L | 2 |
| Caliendo, A | 1 |
| Pollard, RB | 1 |
| Demols, P | 1 |
| Claes, CA | 1 |
| Farber, CM | 1 |
| Rasquin, F | 1 |
| Nakamoto, BK | 1 |
| Dorotheo, EU | 1 |
| Biousse, V | 1 |
| Tang, RA | 1 |
| Schiffman, JS | 1 |
| Newman, NJ | 1 |
| Ausayakhun, S | 1 |
| Watananikorn, S | 1 |
| Ngamtiphakorn, S | 1 |
| Prasitsilp, J | 1 |
| Kitajima, N | 1 |
| Luckie, AP | 3 |
| Wagstaff, AJ | 1 |
| Bryson, HM | 1 |
| Trolliet, P | 1 |
| Dijoud, F | 1 |
| Cotte, L | 1 |
| Cahen, R | 1 |
| François, B | 1 |
| Trepo, C | 1 |
| Patricot, LM | 1 |
| McCann, JD | 1 |
| Margolis, TP | 1 |
| Wong, MG | 1 |
| Kuppermann, BD | 5 |
| Schwartz, DM | 1 |
| Irvine, AR | 2 |
| Ai, E | 2 |
| Blanshard, C | 1 |
| Benhamou, Y | 1 |
| Dohin, E | 1 |
| Lernestedt, JO | 2 |
| Gazzard, BG | 4 |
| Costagliola, D | 2 |
| Mary-Krause, M | 1 |
| Salazar, A | 1 |
| Podzamczer, D | 1 |
| Reñe, R | 1 |
| Santin, M | 1 |
| Perez, JL | 2 |
| Ferrer, I | 1 |
| Fernandez-Viladrich, P | 1 |
| Gudiol, F | 1 |
| Engstrom, RE | 2 |
| Holland, GN | 6 |
| Thimons, JJ | 1 |
| Aweeka, FT | 1 |
| Gambertoglio, JG | 2 |
| Kramer, F | 2 |
| van der Horst, C | 2 |
| Polsky, B | 3 |
| Jayewardene, A | 1 |
| Lizak, P | 1 |
| Emrick, L | 1 |
| Tong, W | 1 |
| Jacobson, MA | 11 |
| Polis, MA | 2 |
| Masur, H | 1 |
| Dunn, JP | 3 |
| MacCumber, MW | 1 |
| Charache, P | 2 |
| Apuzzo, L | 1 |
| Levinson, RD | 1 |
| Raffi, F | 1 |
| Lebrette, MG | 1 |
| el Amrani, M | 1 |
| Monfort, L | 1 |
| Gozlan, J | 2 |
| Girard, PM | 1 |
| Rozenbaum, W | 1 |
| Aguirrebengoa, K | 1 |
| González, R | 1 |
| Oñate, J | 1 |
| Ibáñez de Maeztu, JC | 1 |
| Ruiz-Irastorza, G | 1 |
| Montejo, M | 1 |
| Kaiser, L | 1 |
| Perrin, L | 1 |
| Hirschel, B | 1 |
| Furrer, H | 1 |
| Von Overbeck, J | 1 |
| Olmari, M | 1 |
| Yerly, S | 1 |
| Balfour, HH | 3 |
| Wilcox, CM | 1 |
| Straub, RF | 1 |
| Schwartz, DA | 1 |
| Jones, JL | 2 |
| Hanson, DL | 2 |
| Chu, SY | 1 |
| Ward, JW | 1 |
| Jaffe, HW | 2 |
| Colucciello, M | 1 |
| Moyle, G | 2 |
| Hamprecht, K | 1 |
| Jahn, G | 1 |
| Albrecht, H | 1 |
| Stellbrink, HJ | 1 |
| Brewster, D | 1 |
| Greten, H | 1 |
| Colebunders, R | 1 |
| Van den Abbeele, K | 1 |
| Fleerackers, Y | 1 |
| Bols, K | 1 |
| Lachenal, M | 1 |
| Van Damme, L | 1 |
| Wulfsohn, M | 1 |
| Feinberg, JE | 1 |
| Davis, R | 2 |
| Power, M | 1 |
| Causey, D | 2 |
| Heath-Chiozzi, ME | 1 |
| Murphy, RL | 1 |
| Cheung, TW | 3 |
| Bassiakos, Y | 1 |
| Hooton, T | 1 |
| Geheb, H | 1 |
| O'Donnell, JJ | 2 |
| Walker, JD | 1 |
| Korvick, JA | 1 |
| Morris, DJ | 1 |
| Stamminger, T | 1 |
| Fleckenstein, B | 2 |
| Snoeck, R | 1 |
| Andrei, G | 1 |
| Gérard, M | 1 |
| Silverman, A | 1 |
| Hedderman, A | 1 |
| Balzarini, J | 1 |
| Sadzot-Delvaux, C | 1 |
| Tricot, G | 1 |
| Clumeck, N | 1 |
| De Clercq, E | 1 |
| Karmochkine, M | 1 |
| Molina, JM | 1 |
| Scieux, C | 2 |
| Welker, Y | 1 |
| Morinet, F | 1 |
| Decazes, JM | 1 |
| Lagrange, P | 1 |
| Schnell, L | 1 |
| Modai, J | 1 |
| Nagata, Y | 1 |
| Fujino, Y | 1 |
| Ono, A | 1 |
| Mochizuki, M | 1 |
| Mouri, H | 1 |
| Oka, S | 1 |
| Kimura, S | 1 |
| Shimada, K | 1 |
| Poles, MA | 4 |
| McMeeking, AA | 1 |
| Scholes, JV | 1 |
| Dieterich, DT | 5 |
| Domingo, P | 1 |
| Puig, M | 1 |
| Iranzo, A | 1 |
| Lopez-Contreras, J | 1 |
| Ris, J | 1 |
| Freeman, WR | 6 |
| Stanley, HD | 1 |
| Charlebois, E | 1 |
| Harb, G | 1 |
| Lieberman, RM | 1 |
| Orellana, J | 1 |
| Melton, RC | 1 |
| Diaz-Llopis, M | 1 |
| España, E | 1 |
| Muñoz, G | 1 |
| Navea, A | 1 |
| Chipont, E | 1 |
| Cano, J | 1 |
| Menezo, JL | 1 |
| Romero, FJ | 1 |
| Gerna, G | 7 |
| Baldanti, F | 6 |
| Sarasini, A | 6 |
| Furione, M | 3 |
| Percivalle, E | 4 |
| Revello, MG | 3 |
| Zipeto, D | 1 |
| Zella, D | 2 |
| Geier, SA | 3 |
| Klauss, V | 2 |
| Bogner, JR | 3 |
| Schmidt-Kittler, H | 1 |
| Sadri, I | 2 |
| Goebel, FD | 4 |
| Peters, M | 2 |
| Schürmann, D | 3 |
| Bergmann, F | 2 |
| Grünewald, T | 1 |
| Timm, H | 2 |
| Pohle, HD | 2 |
| Ruf, B | 2 |
| Berman, SM | 1 |
| Kim, RC | 1 |
| Murphy, R | 2 |
| Naughton, K | 2 |
| Flores-Aguilar, M | 3 |
| Quiceno, JI | 4 |
| Rickman, LS | 1 |
| Ricart Olmos, C | 1 |
| López Aldeguer, J | 1 |
| Marino Blanes Juliá, F | 1 |
| Sinelni, E | 1 |
| Roarty, JD | 1 |
| Fisher, EJ | 1 |
| Nussbaum, JJ | 1 |
| Friedberg, DN | 5 |
| Berry, C | 1 |
| Behette, M | 1 |
| Fullerton, SC | 1 |
| Munguia, D | 1 |
| Safrin, S | 1 |
| Kemmerly, S | 1 |
| Plotkin, B | 1 |
| Smith, T | 1 |
| Weissbach, N | 1 |
| De Veranez, D | 1 |
| Phan, LD | 1 |
| Cohn, D | 1 |
| Spaide, RF | 1 |
| Baumann, R | 1 |
| Wunderli, W | 1 |
| Riess, C | 1 |
| Vogt, M | 1 |
| Johnston, WH | 1 |
| Rimmer, S | 1 |
| Heinic, GS | 1 |
| Greenspan, D | 1 |
| Greenspan, JS | 1 |
| Barton, S | 2 |
| Dicker, M | 1 |
| Tepper, R | 1 |
| Lew, E | 1 |
| Brown, DL | 1 |
| Sather, S | 1 |
| Cheitlin, MD | 1 |
| Lew, EA | 2 |
| Mendez, PE | 1 |
| Addessi, A | 1 |
| Pearson, PA | 1 |
| Jaffe, GJ | 1 |
| Ashton, P | 1 |
| Miguélez, M | 2 |
| Linares Feria, M | 1 |
| Laynez, P | 2 |
| Méndez, M | 1 |
| Hengge, UR | 1 |
| Brockmeyer, NH | 1 |
| Malessa, R | 1 |
| Ravens, U | 1 |
| Goos, M | 1 |
| Dankner, WM | 1 |
| Wolf, DG | 1 |
| Capparelli, EV | 1 |
| Connor, JD | 1 |
| Sherwood, CH | 1 |
| Fullerton, S | 1 |
| Bianchi, A | 1 |
| Hardy, D | 1 |
| Chown, M | 1 |
| Heinemann, MH | 2 |
| Keshavjee, SH | 1 |
| Magee, LA | 1 |
| Mullen, BJ | 1 |
| Baron, DL | 1 |
| Brunton, JL | 1 |
| Gallinger, S | 1 |
| Young, LH | 2 |
| Brerra, R | 1 |
| Barbi, M | 2 |
| Giezendanner, S | 1 |
| Wirth, HP | 1 |
| Zala, G | 1 |
| Weber, R | 1 |
| Flury, R | 1 |
| Meyenberger, C | 1 |
| Len, O | 1 |
| de Otero, J | 1 |
| Ribera, E | 1 |
| Ocaña, I | 1 |
| Fillet, AM | 5 |
| Visse, B | 2 |
| Dumont, B | 2 |
| Gentilini, M | 1 |
| Huraux, JM | 2 |
| Navarro, JF | 1 |
| Quereda, C | 3 |
| Gallego, N | 1 |
| Antela, A | 1 |
| Mora, C | 1 |
| Ortuno, J | 1 |
| Cohen, BA | 1 |
| Underwood, MR | 1 |
| Stanat, SC | 1 |
| Biron, KK | 2 |
| Silini, E | 2 |
| Glesby, MJ | 1 |
| Hoover, DR | 2 |
| Weng, S | 1 |
| Graham, NM | 1 |
| Phair, JP | 2 |
| Detels, R | 1 |
| Ho, M | 1 |
| Saah, AJ | 1 |
| Desatnik, HR | 1 |
| Foster, RE | 2 |
| Lowder, CY | 2 |
| Enger, C | 2 |
| Forman, M | 2 |
| Bressler, N | 1 |
| Peng, Y | 1 |
| Saah, A | 1 |
| Semba, R | 1 |
| Detels, RR | 1 |
| Rinaldo, CR | 1 |
| Wu, AW | 1 |
| Coleson, LC | 1 |
| Holbrook, J | 1 |
| Dodds, EM | 1 |
| Avery, RK | 1 |
| Prayson, RA | 1 |
| Lazzarin, A | 1 |
| Bernhard, P | 1 |
| Obel, N | 1 |
| Corral, I | 1 |
| Cobo, J | 1 |
| Casado, JL | 2 |
| Guerrero, A | 2 |
| Castanet, J | 1 |
| Rodot, S | 1 |
| Lacour, JP | 1 |
| Van Elslande, L | 1 |
| Perrin, C | 1 |
| Durant, J | 1 |
| Ortonne, JP | 1 |
| Conn, J | 1 |
| Colman, P | 1 |
| Brown, G | 1 |
| Street, A | 1 |
| Bate, K | 1 |
| Zaman, MM | 1 |
| Burney, S | 1 |
| Landman, D | 1 |
| Quale, JM | 1 |
| Patel, SS | 1 |
| Rutzen, AR | 1 |
| Marx, JL | 1 |
| Thach, AB | 1 |
| Chong, LP | 1 |
| Rao, NA | 3 |
| Fishman, JE | 1 |
| Batt, HD | 1 |
| Soriano, V | 1 |
| Mas, A | 1 |
| Bravo, R | 1 |
| Moreno, V | 1 |
| González-Lahoz, J | 1 |
| Quartier, P | 1 |
| Khouri, J | 1 |
| Maout, F | 1 |
| Courpotin, C | 1 |
| Dollfus, C | 1 |
| Tabone, MD | 1 |
| Leverger, G | 1 |
| Lasfargues, G | 1 |
| Carosi, G | 2 |
| Castelli, F | 2 |
| Antoniazzi, E | 1 |
| Itin, PH | 1 |
| Lautenschlager, S | 1 |
| Breton, G | 2 |
| Crémieux, AC | 1 |
| Bright, DC | 1 |
| Lyon, AT | 1 |
| Hardy, WD | 3 |
| Segal, BH | 1 |
| Engler, HD | 1 |
| Little, R | 1 |
| Wilson, WH | 1 |
| Freifeld, AG | 1 |
| Chanock, SJ | 1 |
| Walton, RC | 1 |
| Whitcup, SM | 2 |
| Mueller, BU | 1 |
| Lewis, LL | 1 |
| Pizzo, PA | 1 |
| Nussenblatt, RB | 1 |
| Mallolas, J | 1 |
| Gatell, JM | 1 |
| Gómez-Sirvent, JL | 1 |
| Buira, E | 1 |
| Zamora, L | 1 |
| Alecrim-Andrade, J | 1 |
| Adán, A | 1 |
| Morales, M | 1 |
| Miró, JM | 1 |
| Lonća, M | 1 |
| Guelar, A | 1 |
| Soriano, E | 1 |
| Cunningham, ET | 2 |
| Moore, DA | 1 |
| Nelson, MR | 1 |
| Fletcher, CV | 1 |
| Erice, A | 2 |
| Henry, WK | 1 |
| Acosta, EP | 1 |
| Smith, SA | 1 |
| Holm, MA | 1 |
| Boivin, G | 6 |
| Shepp, DH | 1 |
| Crumpacker, CS | 1 |
| Eaton, CA | 1 |
| Martin-Munley, SS | 1 |
| Gil-Roda, C | 1 |
| Sannerud, KJ | 1 |
| Hanson, MN | 1 |
| Moorthy, RS | 1 |
| Teich, SA | 2 |
| Berger, BB | 1 |
| Minturn, JT | 1 |
| Kumar, S | 1 |
| Fowell, SM | 1 |
| Loose, IA | 1 |
| Jampol, LM | 1 |
| Mueller, AJ | 1 |
| Hurwitz, S | 1 |
| Chuang, EL | 1 |
| Haidt, SJ | 1 |
| Kaplan, HJ | 1 |
| Martin-Munley, S | 3 |
| Johnson, J | 1 |
| Nix, D | 1 |
| Faust, MJ | 1 |
| Zaknun, D | 1 |
| Zangerle, R | 1 |
| Kapelari, K | 1 |
| Fischer, H | 1 |
| Sailer, M | 1 |
| McIntosh, K | 1 |
| Tomasoni, L | 1 |
| Zeroli, C | 1 |
| Suter, F | 1 |
| Trespi, G | 1 |
| Hedman, A | 1 |
| Speyrer, MP | 1 |
| Marousek, G | 2 |
| Guentzel, S | 1 |
| Follansbee, SE | 1 |
| Poscher, ME | 1 |
| Lalezari, JP | 3 |
| Miner, RC | 2 |
| Drew, WL | 4 |
| Cline, JJ | 1 |
| Garrett, AD | 1 |
| Manfredi, R | 1 |
| Lazzarotto, T | 1 |
| Spezzacatena, P | 1 |
| Dal Monte, P | 1 |
| Mastroianni, A | 1 |
| Coronado, OV | 1 |
| Chiodo, F | 1 |
| Pérez-Blázquez, E | 1 |
| Traspas, R | 1 |
| Méndez Marín, I | 1 |
| Montero, M | 1 |
| Usui, N | 1 |
| Usui, M | 1 |
| Guembel, HO | 1 |
| Hofmann, F | 1 |
| van Even, G | 1 |
| Cinatl, J | 1 |
| Makabe, R | 1 |
| Smith, CL | 1 |
| Lee, MS | 1 |
| Cooney, EL | 1 |
| Stoessel, KM | 1 |
| Gariano, RF | 1 |
| Read, RC | 1 |
| Vilar, FJ | 1 |
| Smith, TL | 1 |
| Pau, AK | 1 |
| Silverstein, BE | 1 |
| Smith, JH | 1 |
| Sykes, SO | 1 |
| Jones, MR | 1 |
| Schwartz, D | 1 |
| Anders, HJ | 1 |
| Weiss, N | 1 |
| Goodgame, RW | 1 |
| Parente, F | 1 |
| Bianchi Porro, G | 1 |
| Scoular, A | 1 |
| Tural, C | 1 |
| Romeu, J | 1 |
| Sirera, G | 1 |
| Andreu, D | 1 |
| Conejero, M | 1 |
| Ruiz, S | 1 |
| Jou, A | 1 |
| Bonjoch, A | 1 |
| Ruiz, L | 1 |
| Arnó, A | 1 |
| Clotet, B | 1 |
| Meenken, C | 1 |
| van den Horn, GJ | 2 |
| de Smet, MD | 1 |
| van der Meer, JT | 2 |
| Ciulla, TA | 1 |
| Rutledge, BK | 1 |
| Morley, MG | 1 |
| Duker, JS | 1 |
| Guery, B | 1 |
| Bochet, M | 1 |
| Deray, G | 1 |
| Monno, L | 1 |
| Di Stefano, M | 1 |
| Zimatore, GB | 1 |
| Andreula, CF | 1 |
| Appice, A | 1 |
| Perulli, LM | 1 |
| Fiore, JR | 1 |
| Pastore, G | 1 |
| Angarano, G | 1 |
| Grobusch, MP | 1 |
| Behnsch, M | 1 |
| Liekfeld, A | 1 |
| Whitley, RJ | 1 |
| Deutsch, TA | 1 |
| Feinberg, J | 1 |
| Spector, SA | 1 |
| Walmsley, S | 1 |
| Powderly, WG | 1 |
| Griffiths, PD | 1 |
| Benson, CA | 1 |
| Kessler, HA | 1 |
| Althaus, C | 2 |
| Loeffler, KU | 1 |
| Schimkat, M | 1 |
| Hudde, T | 1 |
| Sundmacher, R | 1 |
| Park, SS | 1 |
| Girard, B | 1 |
| Font, RL | 1 |
| Hauw, JJ | 1 |
| Ries, E | 1 |
| Mühlbauer, B | 1 |
| Ruhswurm, I | 1 |
| Krepler, K | 1 |
| Derbolav, A | 1 |
| Svolba, G | 1 |
| Rieger, A | 1 |
| Wedrich, A | 1 |
| Parenti, DM | 1 |
| Gordon, SM | 1 |
| LaVoy, AG | 1 |
| Ross, JG | 1 |
| Zavattoni, M | 1 |
| Torsellini, M | 1 |
| Jayaweera, DT | 2 |
| Cassetti, LI | 1 |
| Espinoza, L | 1 |
| Lopardo, GD | 1 |
| Hansman-Whiteman, ML | 1 |
| Scerpella, EG | 1 |
| Maurice-Estepa, L | 1 |
| Daudon, M | 1 |
| Jouanneau, C | 1 |
| Sazdovitch, V | 1 |
| Lacour, B | 1 |
| Beaufils, H | 1 |
| Goldfarb, DS | 1 |
| Coe, FL | 1 |
| Löw, P | 1 |
| Neipel, F | 1 |
| Rascu, A | 1 |
| Steininger, H | 1 |
| Manger, B | 1 |
| Kalden, JR | 1 |
| Harrer, T | 1 |
| Barba, R | 1 |
| Gómez-Rodrigo, J | 1 |
| Marco, J | 1 |
| Espejo, M | 1 |
| Mena, D | 1 |
| Bricaire, F | 1 |
| Verbraak, FD | 1 |
| Paydafar, D | 1 |
| ten Kate, FJ | 1 |
| Wertheim-van Dillen, PM | 1 |
| Kijlstra, A | 1 |
| Gaudreau, A | 1 |
| Toma, E | 2 |
| Lalonde, R | 2 |
| Routy, JP | 1 |
| Murray, G | 1 |
| Handfield, J | 2 |
| Bergeron, MG | 2 |
| Cochereau, I | 1 |
| Belayachi, N | 1 |
| Diraison, C | 1 |
| Matheron, S | 2 |
| Bouyer, I | 1 |
| Hoang-Xuan, T | 1 |
| Saimot, AG | 1 |
| Coulaud, JP | 1 |
| Fuchs, AV | 1 |
| Wolf, E | 1 |
| Scheider, A | 1 |
| Jäger, H | 1 |
| Kampik, A | 1 |
| Wooten, JM | 1 |
| Chase, K | 1 |
| O'Connor, MC | 1 |
| Henry, RB | 1 |
| Justman, J | 1 |
| Zabezhanskaya, M | 1 |
| Iten, A | 1 |
| Chatelard, P | 1 |
| Vuadens, P | 1 |
| Miklossy, J | 1 |
| Meuli, R | 1 |
| Sahli, R | 1 |
| Meylan, PR | 1 |
| Schmit, I | 1 |
| Javaly, K | 1 |
| Wohlfeiler, M | 1 |
| Kalayjian, R | 1 |
| Klein, T | 1 |
| Bryson, Y | 1 |
| Grafford, K | 1 |
| Rabkin, CS | 1 |
| Testa, MA | 1 |
| Huang, J | 1 |
| Von Roenn, JH | 1 |
| Correa-Nazco, VJ | 1 |
| Linares, M | 1 |
| González, M | 1 |
| Martínez, A | 1 |
| Parra Ródenas, JV | 1 |
| Riera Ayora, M | 1 |
| Ronda Gasulla, A | 1 |
| Herrera Ballester, A | 1 |
| Hoy, J | 1 |
| Wutoh, AK | 1 |
| Hidalgo, J | 1 |
| Rhee, W | 1 |
| Bareta, J | 1 |
| Steidl, S | 1 |
| Labetoulle, M | 1 |
| Goujard, C | 1 |
| Frau, E | 2 |
| Rogier, H | 1 |
| Niessen, F | 1 |
| Furlan, V | 1 |
| Lantz, O | 1 |
| Lecointe, D | 1 |
| Delfraissy, JF | 1 |
| Offret, H | 2 |
| Haas, C | 1 |
| Marteau, P | 1 |
| Roudière, L | 1 |
| Gisselbrecht, M | 1 |
| Lowenstein, W | 1 |
| Durand, H | 1 |
| Anduze-Faris, BM | 1 |
| Lancar, R | 1 |
| Boukli, N | 1 |
| Gasnault, J | 1 |
| Livartowsky, J | 1 |
| Leport, C | 2 |
| Salmon, D | 1 |
| Salmon-Céron, D | 2 |
| Aboulker, JP | 1 |
| Gérard, L | 1 |
| Houhou, N | 1 |
| Carrière, I | 1 |
| Ostinelli, J | 1 |
| Vildé, JL | 1 |
| Brun-Vézinet, F | 1 |
| Bini, EJ | 1 |
| Gorelick, SM | 1 |
| Weinshel, EH | 1 |
| Huycke, MM | 1 |
| Naguib, MT | 1 |
| Stroemmel, MM | 1 |
| Blick, K | 1 |
| Monti, K | 1 |
| Kaufman, C | 1 |
| Dworkin, MS | 1 |
| Hubbard, LD | 1 |
| Gilpin, AK | 1 |
| Meinert, C | 1 |
| Reshef, DS | 1 |
| Best, J | 1 |
| Kersten, A | 1 |
| Theisen, A | 1 |
| Gantke, B | 1 |
| Bodaghi, B | 1 |
| Mougin, C | 1 |
| Michelson, S | 1 |
| Dighiero, P | 1 |
| Pearce, D | 1 |
| Benson, P | 1 |
| Nahass, R | 1 |
| Olson, C | 1 |
| Wool, GM | 1 |
| Velez, G | 1 |
| Roy, CE | 1 |
| Chan, CC | 1 |
| Robinson, MR | 1 |
| Blanchet, KD | 1 |
| Bicart-Sée, A | 1 |
| Obadia, M | 1 |
| Gonzalez, C | 1 |
| Averous, S | 1 |
| Maurette, M | 1 |
| Auvergnat, JC | 1 |
| Cheng, B | 2 |
| Smart, T | 2 |
| Highleyman, L | 1 |
| Lee, TA | 1 |
| Sullivan, SD | 1 |
| Veenstra, DL | 1 |
| Ramsey, SD | 1 |
| Steger, PJ | 1 |
| Malinverni, R | 1 |
| Pleil, AM | 1 |
| Williamson, T | 1 |
| Cañizares, MA | 1 |
| Losada, I | 1 |
| Pérez-Elías, MJ | 1 |
| González, J | 1 |
| Rubio, R | 1 |
| Aoki, FY | 1 |
| Gershon, AA | 1 |
| Bestman-Smith, J | 1 |
| Franco-Paredes, C | 1 |
| Bellehemeur, T | 1 |
| Merchant, A | 1 |
| Sanghi, P | 1 |
| DiazGranados, C | 1 |
| Rimland, D | 1 |
| Williams, IG | 1 |
| Reusser, P | 1 |
| Keefe, KS | 1 |
| Peterson, TJ | 1 |
| Wiley, CA | 1 |
| Crapotta, J | 1 |
| Listhaus, AD | 1 |
| Bachman, DM | 1 |
| Bruni, LM | 1 |
| DiGioia, RA | 1 |
| Harris, PJ | 1 |
| McMackin, CM | 1 |
| Pistole, MC | 1 |
| Thomas, RM | 1 |
| Ward, DJ | 1 |
| Silvia, PA | 1 |
| Matuschke, A | 1 |
| Kronawitter, U | 1 |
| Morinelli, EN | 1 |
| Dugel, PU | 1 |
| Lee, M | 1 |
| Klatt, EC | 1 |
| Schmitz, K | 1 |
| Fabricius, EM | 1 |
| Popescu, M | 1 |
| Saint-Marc, T | 1 |
| Fournier, F | 1 |
| Touraine, JL | 1 |
| Marneff, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component[NCT00000665] | 240 participants | Interventional | Completed | ||||
| A Phase II, Double-Masked, Randomized, Placebo-Controlled Evaluation of Standard Therapy vs. Standard Therapy Combined With Human Monoclonal Anti-Cytomegalovirus Antibody (MSL 109) in the Therapy of AIDS Patients With Cytomegalovirus (CMV) Retinitis[NCT00001061] | Phase 2 | 167 participants | Interventional | Completed | |||
| Foscarnet-Ganciclovir CMV Retinitis Trial[NCT00000136] | Phase 3 | 234 participants (Actual) | Interventional | 1990-03-31 | Completed | ||
| A Phase I Open-Labeled Study of Long Term Combined or Alternating Foscarnet/Ganciclovir Maintenance Therapy for AIDS Patients With CMV Retinitis After Ganciclovir Induction Therapy[NCT00000970] | Phase 1 | 30 participants | Interventional | Completed | |||
| A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure[NCT00000691] | Phase 2 | 156 participants | Interventional | Completed | |||
| [NCT00005228] | 0 participants | Observational | 1988-07-31 | Completed | |||
| Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome[NCT00000726] | Phase 1 | 53 participants | Interventional | Completed | |||
| Cytomegalovirus Retinitis Retreatment Trial[NCT00000134] | Phase 3 | 279 participants (Actual) | Interventional | 1992-12-31 | Completed | ||
| Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease[NCT00002145] | Phase 3 | 145 participants | Interventional | Completed | |||
| A Multi-centered, Randomized Study to Evaluate the Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection Compared to Intravenous Acyclovir in Patients With Herpes Zoster From China[NCT02151240] | Phase 4 | 94 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| A Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunction With An Intravitreal Ganciclovir Implant in the Treatment of Cytomegalovirus Retinitis[NCT00002134] | 450 participants | Interventional | Completed | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00000136)
Timeframe: All patients enrolled will be followed until a common study closing date, which was chosen to provide a minimum of 1 year of follow-up for all patients enrolled in the trial.
| Intervention | participants (Number) |
|---|---|
| Foscarnet | 107 |
| Ganciclovir | 127 |
To determine the best therapeutic regimen, using currently approved drugs, for treatment of relapsed cytomegalovirus (CMV) retinitis. (NCT00000134)
Timeframe: Patients will be seen at baseline, monthly for six months, and then every three months until death or termination of the trial
| Intervention | participants (Number) |
|---|---|
| Intravenous Foscarnet | 88 |
| Intravenous Ganciclovir | 93 |
| Combination Therapy | 93 |
44 reviews available for foscarnet and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
[Drugs against human cytomegalovirus].
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infec | 2002 |
Progressive outer retinal necrosis presenting with isolated optic neuropathy.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infection | 2004 |
[Therapy for cytomegalovirus infection].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Ganc | 2006 |
Cytomegalovirus retinitis in patients with AIDS: current status.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Foscarnet; Ganci | 1995 |
Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus; Drug Administration Schedule; Drug Interacti | 1994 |
Local therapy for cytomegalovirus retinopathy.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents, Local; Cytomegalovirus Retinitis; Dela | 1995 |
CMV retinitis treatment.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Foscarnet; Ganciclovir; Humans | 1995 |
Promising new treatments for cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Cidofovir; Cytomegalovirus Retinitis; Cytosine; Drug Implants | 1995 |
[Cytomegalovirus infections in AIDS].
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Cytomegalovirus Infection | 1995 |
Current management of cytomegalovirus disease in patients with AIDS.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Drug Therapy, Combination; Foscarn | 1994 |
Cytomegalovirus retinitis in persons with AIDS. Selecting therapy for a sight-threatening disease.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Foscarnet; Ganciclovir; Humans; Mu | 1995 |
Adverse effects and drug interactions of clinical importance with antiviral drugs.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Amantadine; Antiviral Agents; Didanosine; Drug Int | 1994 |
Retinal disease associated with AIDS.
Topics: AIDS-Related Opportunistic Infections; CD4-Positive T-Lymphocytes; Cytomegalovirus Infections; Eye I | 1993 |
Oral CMV lesions and the HIV infected. Early recognition can help prevent morbidity.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Foscarnet; Ganciclovir; HIV Infec | 1993 |
[Resistance of herpes simplex viruses to antiviral drugs].
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; AIDS-Related Opportunistic Infections; DNA-Directed D | 1993 |
Controversies in the treatment of cytomegalovirus retinitis: foscarnet versus ganciclovir.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus R | 1995 |
Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy.
Topics: Acidosis, Renal Tubular; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalov | 1996 |
A foveal-sparing pattern of cytomegalovirus retinitis in the acquired immunodeficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Disease P | 1996 |
Cytomegalovirus polyradiculopathy treated successfully with foscarnet.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Foscarne | 1996 |
Current management of cytomegalovirus retinitis in AIDS update on ganciclovir and foscarnet for CMV infections.
Topics: AIDS-Related Opportunistic Infections; Animals; Antiviral Agents; Cytomegalovirus Retinitis; Foscarn | 1996 |
Viral lesions of the mouth in HIV-infected patients.
Topics: 2-Aminopurine; Acyclovir; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Cytomegalovirus In | 1997 |
[Treatment of cytomegalovirus infections in HIV infection].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Cytomegalovirus | 1996 |
Pharmacologic management of cytomegalovirus retinitis: review of current and future therapeutic modalities.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Foscarnet; Ganci | 1997 |
Cytomegalovirus retinitis: diagnosis and status of systemic therapy.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Diagnosis, Diffe | 1997 |
Management strategies for patients with cytomegalovirus retinitis.
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalo | 1997 |
Therapeutic options for resistant cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus | 1997 |
Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalo | 1997 |
Combination antiviral therapy for cytomegalovirus disease in patients with AIDS.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, C | 1997 |
Management of CMV retinitis in HIV infected patients.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Clinical Trials as Topic; Cytome | 1997 |
New treatment options for CMV retinitis in AIDS.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Therapy, Co | 1997 |
[Cytomegalovirus retinitis].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; Cytomegalovirus Retin | 1998 |
Local therapy for cytomegalovirus retinitis.
Topics: Administration, Topical; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; C | 1998 |
Ganciclovir and foscarnet efficacy in AIDS-related CMV polyradiculopathy.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Inf | 1998 |
Cytomegalovirus infection in patients with HIV infection.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cyto | 1999 |
Clinically resistant cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Retinitis; | 1995 |
Cytomegalovirus: disease syndromes and treatment.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Central Nervous System Diseases; Chorioreti | 1999 |
Management of CMV infections in HIV-infected patients.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Retinitis; Cytos | 1999 |
Economic evaluation of systemic treatments for cytomegalovirus retinitis in patients with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Retinitis | 2001 |
Cytomegalovirus infection: the point in 2001.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiv | 2001 |
Management of genital herpes in HIV-infected patients.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral A | 2001 |
Prevention and treatment of VZV infections in patients with HIV.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Chickenpox; Chickenpox Va | 2001 |
Aseptic meningitis and optic neuritis preceding varicella-zoster progressive outer retinal necrosis in a patient with AIDS.
Topics: Adrenal Cortex Hormones; Adult; AIDS-Related Opportunistic Infections; Anti-Inflammatory Agents; Ant | 2002 |
Management of CMV disease in HIV infection.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cyto | 1999 |
[Clinical aspects and therapy of infection with cytomegalovirus].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Ganc | 1992 |
43 trials available for foscarnet and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Antibodies, Monoclonal; Antiretroviral Therapy, Highly | 2003 |
Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cohort Studies; Cytomegalovirus; Cyt | 2003 |
A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus re
Topics: Adult; AIDS-Related Opportunistic Infections; Antibodies, Monoclonal; Antiviral Agents; Cytomegalovi | 2004 |
Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus; Drug Administration Schedule; Drug Interacti | 1994 |
Antiviral effects of foscarnet and ganciclovir therapy on human immunodeficiency virus p24 antigen in patients with AIDS and cytomegalovirus retinitis. Studies of Ocular Complications of AIDS Research Group in collaboration with AIDS Clinical Trials Group
Topics: AIDS-Related Opportunistic Infections; Antigen-Antibody Complex; Cytomegalovirus Retinitis; Female; | 1995 |
Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison.
Topics: Adult; AIDS-Related Opportunistic Infections; Antigens, Viral; Cytomegalovirus; Cytomegalovirus Infe | 1995 |
Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Drug Administration Schedul | 1995 |
Dose-related difference in progression rates of cytomegalovirus retinopathy during foscarnet maintenance therapy. AIDS Clinical Trials Group Protocol 915 Team.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Re | 1995 |
Foscarnet decreases human immunodeficiency virus RNA.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Cyt | 1995 |
Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group.
Topics: Acute Kidney Injury; Adolescent; Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retin | 1995 |
Foscarnet or ganciclovir for treatment of AIDS and CMV retinitis.
Topics: AIDS-Related Opportunistic Infections; Clinical Trials as Topic; Cytomegalovirus Retinitis; Foscarne | 1995 |
Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG protocol 093). AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Drug Resi | 1994 |
Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Cells, Cultured; Clinical Protocols; Cytom | 1994 |
Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Female; Foscarnet; Fundus O | 1994 |
High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Female; Foscarnet; Humans; | 1994 |
Effect of foscarnet induction treatment on quantitation of human cytomegalovirus (HCMV) DNA in peripheral blood polymorphonuclear leukocytes and aqueous humor of AIDS patients with HCMV retinitis. The Italian Foscarnet Study Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Aqueous Humor; Cytomegalovirus; Cytomegalovirus Retini | 1994 |
Safety of alternating ganciclovir and foscarnet maintenance therapy in human immunodeficiency virus (HIV)-related cytomegalovirus infections. An open-labeled pilot study.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Drug Administration Schedu | 1994 |
Foscarnet treatment of cytomegalovirus gastrointestinal infections in acquired immunodeficiency syndrome patients who have failed ganciclovir induction.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Drug Resistance; Foscarnet | 1993 |
A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Foscarne | 1993 |
Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Ther | 1996 |
Controversies in the treatment of cytomegalovirus retinitis: foscarnet versus ganciclovir.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus R | 1995 |
Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Antiviral Agents; Bisexuality; Case-Control Studie | 1996 |
Assessment of cytomegalovirus retinitis. Clinical evaluation vs centralized grading of fundus photographs. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Disease P | 1996 |
Measuring visual function and quality of life in patients with cytomegalovirus retinitis. Development of a questionnaire. Studies of Ocular Complication of AIDS Research Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cross-Sectional Studies; Cytomegalov | 1996 |
Clinical vs photographic assessment of treatment of cytomegalovirus retinitis. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial Report 8. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Foscarnet | 1996 |
Convenient twice daily foscarnet in induction therapy of AIDS-associated cytomegalovirus retinitis. The Foscarnet Italian Study Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Admi | 1997 |
[Prophylaxis secondary to retinitis by CMV in patients with AIDS: the efficacy of an intermittent schedule of 3 days/week].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Admi | 1997 |
Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; | 1996 |
Treatment of gastrointestinal cytomegalovirus infection with twice-daily foscarnet: a pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Animals; Antiviral | 1997 |
Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir. Studies of Ocular Complications of AIDS (SOCA) in collaboration with the AIDS Clinical Trial Group.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections | 1997 |
Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: the Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS (SOCA) Research Group in Collaboration with the AIDS Clinical Trials Group
Topics: Adolescent; Adult; Age Factors; AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphoc | 1997 |
Comparison of pharmacokinetics and dynamics of two dosage regimens of foscarnet in AIDS patients with Cytomegalovirus retinitis.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Calcium; Cytomegalovirus | 1997 |
Treatment of cytomegalovirus esophagitis in patients with acquired immune deficiency syndrome: a randomized controlled study of foscarnet versus ganciclovir. The Italian Cytomegalovirus Study Group.
Topics: AIDS-Related Opportunistic Infections; Biopsy; Cytomegalovirus Infections; Esophagitis; Foscarnet; G | 1998 |
Renal tolerance of combined treatment with foscarnet and indinavir.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Drug The | 1998 |
[Cytomegalovirus polyradiculomyelopathy in AIDS].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Drug The | 1998 |
Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: a phase I/II study.
Topics: Acyclovir; Administration, Topical; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; | 1999 |
Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: incidence and outcome over 2 years.
Topics: Adult; AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Cytomegalovirus Retinitis; Drug | 1999 |
Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovir | 2000 |
Effect of a 14-day course of foscarnet on cytomegalovirus (CMV) blood markers in a randomized study of human immunodeficiency virus-infected patients with persistent CMV viremia. Agence National de Recherche du SIDA 023 Study Group.
Topics: AIDS-Related Opportunistic Infections; Antigens, Viral; Antiviral Agents; Biomarkers; Cytomegaloviru | 1999 |
A double-blind placebo-controlled crossover trial of intravenous magnesium sulfate for foscarnet-induced ionized hypocalcemia and hypomagnesemia in patients with AIDS and cytomegalovirus infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Calcium; Cross-Ove | 2000 |
Risk factors for advancement of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Studies of Ocular Complications of AIDS Research Group.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; CD8-Positive T-Lymphocytes; Cytomegalovirus | 2000 |
Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovirus infections.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; AIDS-Related Opportunistic Infectio | 2000 |
Foscarnet administered by portable infusion device in AIDS patients with CMV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Dose-Res | 1997 |
158 other studies available for foscarnet and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Management of ganciclovir-resistant cytomegalovirus retinitis in HIV infection in the era of antiretroviral therapy.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Foscarnet; HIV I | 2014 |
Long-term follow-up of HIV-infected patients once diagnosed with acyclovir-resistant herpes simplex virus infection.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytosine; Drug | 2014 |
Perivascular hypofluorescence in frosted branch angiitis.
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; | 2015 |
Management of cytomegalovirus retinitis in HIV infection in the era of highly active antiretroviral therapy.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Foscarnet; Human | 2015 |
Progressive hypertrophic genital herpes in an HIV-infected woman despite immune recovery on antiretroviral therapy.
Topics: Administration, Topical; Adult; AIDS-Related Opportunistic Infections; Aminoquinolines; Antineoplast | 2008 |
Successful treatment of cytomegalovirus polyradiculopathy in a 9-year-old child with congenital human immunodeficiency virus infection.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Brain; Child; Cytomegalovirus Infections; D | 2009 |
Mortality associated with resistant cytomegalovirus among patients with cytomegalovirus retinitis and AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agent | 2010 |
Anogenital pseudotumoral herpes and HIV infection: a new challenge for diagnosis and treatment.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Carcinoma, Squamous Cell; Cidofovir; | 2012 |
Antiviral therapy for cytomegalovirus infections in pediatric patients.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adolescent; Adult; AIDS-Related Opportunis | 2002 |
Intravitreal antivirals in the management of patients with acquired immunodeficiency syndrome with progressive outer retinal necrosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Therapy, Combination; Female; F | 2002 |
Novel mutations in the thymidine kinase and DNA polymerase genes of acyclovir and foscarnet resistant herpes simplex viruses infecting an immunocompromised patient.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; DNA-Directed DNA Polymera | 2002 |
[Bilateral uveitis with definitive hypotony caused by systemic cidofovir].
Topics: AIDS-Related Opportunistic Infections; Cidofovir; Ciliary Body; Cytomegalovirus Retinitis; Cytosine; | 2003 |
Macular CMV retinitis: a case report.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Fatal Out | 2004 |
Intravitreal foscarnet for cytomegalovirus retinitis in patients with AIDS.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Fem | 2005 |
FDA notifications. FDA approves generic foscarnet sodium injection.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Approval; F | 2005 |
Drugs for AIDS and associated infections.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifunga | 1995 |
Crescentic glomerulonephritis and crystals within glomerular capillaries in an AIDS patient treated with foscarnet.
Topics: Adult; AIDS-Related Opportunistic Infections; Crystallization; Cytomegalovirus Retinitis; Foscarnet; | 1995 |
A sensitive and specific polymerase chain reaction-based assay for the diagnosis of cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Base Sequence; Cytomegalovirus; Cytomegalovirus Retinitis; DN | 1995 |
Can antiviral agents decrease the occurrence of Kaposi's sarcoma? Clinical Epidemiology Group from Centres d'Information et de Soins de l'Immunodéficience Humaine.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Antiviral Agents; Bias; Female; Follow-Up Studies; | 1995 |
Cytomegalovirus ventriculoencephalitis in AIDS patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Autopsy; Brain; Cerebral Ventricles; Cerebrospinal Flu | 1995 |
Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus; Cytomegalovirus Retinitis; Disease Pr | 1995 |
[Lesions of the conus medullaris and the cauda equina caused by cytomegalovirus in HIV infection. 7 cases].
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Cauda Equina; Cyto | 1995 |
[Foscarnet related vulvar ulcers. Description of 2 AIDS patients].
Topics: Adult; AIDS-Related Opportunistic Infections; Female; Foscarnet; Humans; Ulcer; Vulvar Diseases | 1995 |
Intraocular sustained drug release devices.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Delayed-Action Preparations; Drug | 1995 |
Cytomegalovirus esophagitis in AIDS: a prospective evaluation of clinical response to ganciclovir therapy, relapse rate, and long-term outcome.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Drug Administration Schedu | 1995 |
AIDS-associated Kaposi's sarcoma.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; AIDS-Related Opportunistic Infections; Female; Foscar | 1995 |
Phosphonoformate for CMV retinitis in AIDS.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Drug Administration Schedule; Fosc | 1995 |
[Cytomegaloviruses--clinical aspects and therapy].
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans | 1994 |
Resolution of oral hairy leukoplakia during treatment with foscarnet.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Foscarnet; Herpesviridae In | 1994 |
Two AIDS patients with life-threatening pancreatitis successfully treated, one with ganciclovir the other with foscarnet.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Female; Foscarnet; Gancicl | 1994 |
[Current developments in antiviral chemotherapy. Part 4: Foscarnet, zidovudine, didanosine].
Topics: AIDS-Related Opportunistic Infections; Didanosine; Dose-Response Relationship, Drug; Drug Administra | 1994 |
Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).
Topics: Acyclovir; Administration, Topical; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; | 1994 |
Combined therapy with ganciclovir and foscarnet for cytomegalovirus polyradiculomyelitis in patients with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Drug Therapy, Combination; | 1994 |
[Foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome].
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Re | 1994 |
Actinomyces infection of a cytomegalovirus esophageal ulcer in two patients with acquired immunodeficiency syndrome.
Topics: Actinomycosis; Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Esophageal | 1994 |
Polyradiculopathy due to cytomegalovirus infection: report of a case in which an AIDS patient responded to foscarnet therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus; C | 1994 |
Central venous catheter infections in AIDS patients receiving treatment for cytomegalovirus disease.
Topics: AIDS-Related Opportunistic Infections; Bacterial Infections; Catheterization, Central Venous; Cathet | 1994 |
Efficacy of intravitreal foscarnet in a patient with AIDS.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Foscarnet; Humans; Injections; Mal | 1994 |
Retinal detachment in patients with acquired immunodeficiency syndrome.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Follow-Up Studie | 1994 |
The development of cytomegalovirus encephalitis in AIDS patients receiving ganciclovir.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Cerebral Ventricles; Confusion; Cytomegalovirus | 1994 |
Combined daily therapy with intravenous ganciclovir and foscarnet for patients with recurrent cytomegalovirus retinitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Drug Administration Schedul | 1994 |
Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Drug Resistance, Microbial; | 1993 |
[Herpes zoster during foscarnet treatment in an AIDS patient].
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis | 1993 |
Long-term visual morbidity of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Foscarnet; Ganciclovir; Hum | 1993 |
Risk factors for development of rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Follow-Up Studies; Foscarnet; Ganc | 1993 |
Foscarnet-resistant herpes simplex virus infection in patients with AIDS.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Drug Resistance, Microbial; Drug Therapy, C | 1994 |
Ganciclovir intraocular device and patient survival.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis | 1994 |
Ganciclovir intraocular device and patient survival.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis | 1994 |
[Acyclovir-resistant Herpes simplex viruses in HIV-infected patients].
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Drug Resistance, Microbial; Female; Foscarn | 1993 |
Recurrence of presumed varicella-zoster virus retinopathy in patients with acquired immunodeficiency syndrome.
Topics: Acyclovir; Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Foscarnet; Fundus Ocu | 1993 |
Penile ulceration with foscarnet therapy.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Foscarnet; Humans; Male; Penile D | 1993 |
Reversible cardiac dysfunction associated with foscarnet therapy for cytomegalovirus esophagitis in an AIDS patient.
Topics: Acquired Immunodeficiency Syndrome; Acute Disease; Adult; AIDS-Related Opportunistic Infections; Cyt | 1993 |
Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Demography; Drug Therapy, | 1993 |
Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Eye Infections, Viral; Foscarnet; | 1993 |
[Foscarnet and genital lesions].
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Foscarnet; Humans; Male; P | 1993 |
Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Blood-Brain Barrier; Cytomegalovirus Infections; Encep | 1993 |
Pathophysiology and treatment of clinically resistant cytomegalovirus retinitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus; Cytomegalovirus Infections; Drug Resi | 1993 |
Acalculous cholecystitis associated with cytomegalovirus and sclerosing cholangitis in a patient with acquired immunodeficiency syndrome.
Topics: Abdominal Pain; Acute Disease; Adult; AIDS-Related Opportunistic Infections; Ampulla of Vater; Biops | 1993 |
Therapy for cytomegalovirus retinitis: still no silver lining.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus R | 1996 |
Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cell Line; Cytomegalovirus; Cytomega | 1995 |
[Clinical manifestations and course of cytomegalovirus colitis in AIDS patients].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cohort Studies; Colitis; Colonoscopy | 1995 |
[Ulcer in the urethral meatus and HIV infection].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Drug Eru | 1995 |
Foscarnet-resistant multidermatomal zoster in a patient with AIDS.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Resistance, Microbia | 1995 |
Prognosis and response to therapy of cytomegalovirus encephalitis and meningomyelitis in AIDS.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Base Sequence; Cerebrospi | 1996 |
Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered f
Topics: AIDS-Related Opportunistic Infections; Amino Acid Sequence; Base Sequence; Cytomegalovirus; Cytomega | 1996 |
Treatment of clinically resistant cytomegalovirus retinitis with combined intravitreal injections of ganciclovir and foscarnet.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Ret | 1996 |
Cytomegalovirus retinitis and viral resistance. Prevalence of resistance at diagnosis, 1994. Cytomegalovirus Retinitis and Viral Resistance Study Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Baltimore; Cytomegalovirus; Cytomega | 1996 |
Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lympho | 1996 |
Serous retinal detachments in a patient with clinically resistant cytomegalovirus retinitis.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomega | 1996 |
Four dually resistant human cytomegalovirus strains from AIDS patients: single mutations in UL97 and UL54 open reading frames are responsible for ganciclovir- and foscarnet-specific resistance, respectively.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections | 1995 |
Treatment of cytomegalovirus retinitis in patients with AIDS.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cyto | 1996 |
New developments in the treatment of CMV retinitis.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Retinitis; Cytos | 1996 |
Chronic ulcerating acyclovir-resistant varicella zoster lesions in an AIDS patient.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Chronic Disease; Drug Res | 1995 |
Chronic varicella presenting as disseminated pinpoint-sized papules in a man infected with the human immunodeficiency virus.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Chickenpox; Chronic Disea | 1996 |
Nephrogenic diabetes insipidus associated with foscarnet--a case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; | 1996 |
Rapid development of renal insufficiency with the simultaneous administration of amphotericin B and foscarnet.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antiviral Agents; C | 1996 |
Cytomegalovirus papillitis in patients with acquired immune deficiency syndrome. Visual prognosis of patients treated with ganciclovir and/or foscarnet.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Cytomega | 1996 |
Cytomegalovirus pneumonia manifesting as a focal mass in acquired immunodeficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Biopsy, Needle; Cytomegalovirus Infe | 1996 |
[Long term survival in an HIV-immunosuppressed patient treated with foscarnet].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; Cytomegaloviru | 1996 |
[Early diagnosis and treatment of cytomegalovirus polyradiculoneuritis in a child infected by HIV].
Topics: AIDS-Related Opportunistic Infections; Child; Cytomegalovirus Infections; Drug Therapy, Combination; | 1996 |
Repair of retinal detachments due to herpes varicella-zoster virus retinitis in patients with acquired immune deficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Foscarnet; Ganciclovir; Herpes Zoste | 1997 |
Early foscarnet failure in herpes simplex virus infection in a patient with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Foscarnet; Herpes Simplex; Humans; M | 1997 |
Combined intravenous ganciclovir and foscarnet for children with recurrent cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Child; Child, Preschool; Cytomegalovirus Re | 1995 |
Quantitative systemic and local evaluation of the antiviral effect of ganciclovir and foscarnet induction treatment on human cytomegalovirus gastrointestinal disease of patients with AIDS. Italian Foscarnet GID Study Group.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections | 1997 |
New therapies for cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cyto | 1997 |
Central venous line infections in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; | 1997 |
Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Base Sequence; Cytomegalovirus; Cytomegalov | 1997 |
Management of varicella zoster virus retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; AIDS-Related Opportunistic Infections; Analysi | 1997 |
Re-evaluation of time to progression of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients clinically resistant to ganciclovir.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Disease Progress | 1997 |
Concurrent ganciclovir and foscarnet treatment for cytomegalovirus encephalitis and retinitis in an infant with acquired immunodeficiency syndrome: case report and review.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, C | 1997 |
Identification and treatment of cytomegalovirus retinitis in patients with AIDS.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; Cytomegalovirus Retin | 1997 |
Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Cidofovir; Cytomega | 1997 |
Quantitative cytomegalovirus (CMV) antigenaemia during antiviral treatment of AIDS-related CMV disease.
Topics: Adult; AIDS-Related Opportunistic Infections; Antigens, Viral; Antiviral Agents; Biomarkers; Cytomeg | 1997 |
Intravitreal ganciclovir treatment in progressive outer retinal necrosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Disease P | 1997 |
Therapy with a combination of intravitreal foscarnet and intravenous ganciclovir in clinically resistant cytomegalovirus retinitis and patients with acquired immunodeficiency syndrome.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus R | 1996 |
Varicella zoster virus retrobulbar optic neuritis preceding retinitis in patients with acquired immune deficiency syndrome.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cerebrospinal Fluid; Fema | 1998 |
AIDS-related herpes simplex virus encephalitis during maintenance foscarnet therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Antiviral Agents; Cell Line; Chlorocebus aeth | 1998 |
New issues in the management of cytomegalovirus retinitis in AIDS patients.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Retinitis; Cytos | 1998 |
Cystoid macular edema associated with cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
Topics: Acetazolamide; Adult; AIDS-Related Opportunistic Infections; Anti-Inflammatory Agents, Non-Steroidal | 1998 |
How to treat the cytomegalovirus troll.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; DNA, Viral; Fos | 1998 |
Therapy for genital herpes in immunocompromised patients: a national survey. The Herpes Simplex Advisory Panel.
Topics: 2-Aminopurine; Acyclovir; AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Resistance, | 1997 |
Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD4 Lymphocyte Count; Cytomegalovirus | 1998 |
Optic neuritis heralding varicella zoster virus retinitis in a patient with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antivir | 1998 |
The progressive outer retinal necrosis syndrome: successful treatment with combination antiviral therapy.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis | 1998 |
Measurement of viral sequences in cerebrospinal fluid of AIDS patients with cerebral white-matter lesions using polymerase chain reaction.
Topics: Adolescent; Adult; AIDS Dementia Complex; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Br | 1998 |
Lack of efficacy of cidofovir in treating AIDS-related cytomegalovirus retinitis after long-term treatment with ganciclovir.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Cidofovir; Cytomegalovirus Retinitis; | 1998 |
Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Cidofovir; Cytomegalovirus | 1998 |
Prophylactic argon laser coagulation for rhegmatogenous retinal detachment in AIDS patients with cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Foscarnet; Fundu | 1998 |
Immunohistochemical localization of ganciclovir in the human retina.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Delayed-A | 1998 |
Evaluation of cytomegalovirus retinitis management. Outcome of four years of cytomegalovirus therapy.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Body Fluids; CD4 Lymphocyte Count; Cytomega | 1998 |
Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Alanine; Antiviral Agents; Cytomegalovirus; Cytomegalo | 1998 |
Diagnostic significance and clinical impact of quantitative assays for diagnosis of human cytomegalovirus infection/disease in immunocompromised patients.
Topics: AIDS-Related Opportunistic Infections; Antibodies, Monoclonal; Antigens, Viral; Antiviral Agents; Ce | 1998 |
Identification of crystals in kidneys of AIDS patients treated with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; | 1998 |
Foscarnet crystal deposition and renal failure.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Crystallization; Cytomegalovirus Retinitis; | 1998 |
Suppression of HHV-8 viremia by foscarnet in an HIV-infected patient with Kaposi's sarcoma and HHV-8 associated hemophagocytic syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; DNA, Viral; Foscarnet; Herpesvirus 8 | 1998 |
Cytomegalovirus retinitis and viral resistance: 3. Culture results. CMV Retinitis and Viral Resistance Study Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Baltimore; Blood; Cidofovir; Cytomeg | 1998 |
Transient foscarnet-induced hypercalcaemia.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Female; F | 1998 |
Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Amino Acid Sequence; Amino Acid Substitution; Antivira | 1998 |
Acyclovir-resistant herpes zoster in human immunodeficiency virus-infected patients: results of foscarnet therapy.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Drug Res | 1998 |
Risk of developing CMV retinitis following non-ocular CMV end organ disease in AIDS patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Biopsy; Cytomegalovirus Infections; | 1998 |
Human herpesvirus 8 DNA load in leukocytes of human immunodeficiency virus-infected subjects: correlation with the presence of Kaposi's sarcoma and response to anticytomegalovirus therapy.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Ganc | 1999 |
[Treatment of CMV retinitis with intravitreal foscarnet].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Disease Progress | 1998 |
[Cytomegalovirus (CMV) retinitis in AIDS. Gancilovir implantation in comparison with systemic therapy].
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Cyto | 1999 |
Dosing guidelines for foscarnet and trimetrexate.
Topics: AIDS-Related Opportunistic Infections; Clinical Protocols; Dose-Response Relationship, Drug; Foscarn | 1995 |
Expression of the late cytomegalovirus (CMV) pp150 transcript in leukocytes of AIDS patients is associated with a high viral DNA load in leukocytes and presence of CMV DNA in plasma.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections | 1999 |
Images in clinical medicine. Severe herpes simplex infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Face; Foscarnet; Herpes Simplex; Hum | 1999 |
Impact of cerebrospinal fluid PCR on the management of HIV-infected patients with varicella-zoster virus infection of the central nervous system.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Central Nervous System In | 1999 |
Characterization of the DNA polymerase and thymidine kinase genesof herpes simplex virus isolates from AIDS patients in whom acyclovirand foscarnet therapy sequentially failed.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Antiviral Agents; DNA-Directed DNA Polymerase; Dru | 1999 |
Kaposi's sarcoma and non-Hodgkin's lymphoma incidence trends in AIDS Clinical Trial Group study participants.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; | 1999 |
[Lumbosacral polyradiculomyelitis caused by herpes simplex virus (HSV) in a patient with AIDS].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; DNA, Viral; Foscarnet; Herpes Simple | 1999 |
[Lumbosacral and meningeal polyradicular disease in a patient with HIV infection].
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Antiviral Agents; Brain; Cytome | 1999 |
Survival differences associated with treatment of cytomegalovirus retinitis in Maryland patients with AIDS, 1987-1994.
Topics: Adult; Age Factors; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Cytome | 1999 |
[Severe cytomegalovirus enteritis in AIDS. Favorable outcome of medical treatment].
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Celiac Disease; Cytomegalovirus Infec | 2000 |
Outcome of AIDS-associated cytomegalovirus colitis in the era of potent antiretroviral therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cohort Studies; Colitis; Cytomegalov | 2000 |
Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Drug Therapy, Combination; | 2000 |
[Stopping secondary prevention in AIDS patients with inactive CMV retinitis treated with HAART (highly active antiretroviral therapy)].
Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cido | 2000 |
Acyclovir-resistant bilateral keratitis associated with mutations in the HSV-1 thymidine kinase gene.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Amino Acid Sequence; Antiviral Agents; Base | 2000 |
High-dose intravitreal ganciclovir and foscarnet for cytomegalovirus retinitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Ther | 2001 |
CMV retinitis: a clinical management update.
Topics: AIDS-Related Opportunistic Infections; Algorithms; Antiviral Agents; Cidofovir; Clinical Protocols; | 1996 |
Support for new foscarnet indication for AIDS-related CMV retinitis is mixed.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Combination | 1997 |
Advances in the treatment of CMV.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Clinical Trials, Phase I as Topi | 1995 |
New drug applications sought.
Topics: AIDS-Related Opportunistic Infections; Clarithromycin; Cytomegalovirus Retinitis; Drug Approval; Dru | 1995 |
International Congress on Chemotherapy.
Topics: Adjuvants, Immunologic; AIDS-Related Opportunistic Infections; Aminoquinolines; Anti-Bacterial Agent | 1995 |
CMV: the other virus.
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retin | 1996 |
Guide to CMV management.
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infec | 1996 |
Two-drug treatment effective against recurrent CMV retinitis.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Therapy, Co | 1996 |
Foscavir receives new indication.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Therapy, Co | 1997 |
Fomivirsen.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Clinical Trials as Topic; Cytome | 1998 |
[Cytomegalovirus sensitivity to anti-retroviral agents in patients infected with the human immunodeficiency virus with chorioretinitis in Spain].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Chorioretinitis; Cytomegalovirus; Cy | 2001 |
Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy.
Topics: Adenine; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Foscarnet; Herpes Genitalis; Herpes | 2002 |
Atypical healing of cytomegalovirus retinitis. Significance of persistent border opacification.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections | 1992 |
Visual field testing in the management of cytomegalovirus retinitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Eye Infe | 1992 |
When you give foscarnet to patients at home.
Topics: AIDS-Related Opportunistic Infections; Community Health Nursing; Cytomegalovirus Infections; Foscarn | 1992 |
2.5 years survival with sequential ganciclovir/foscarnet treatment in a patient with acquired immune deficiency syndrome and cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Cataract Extraction; Cytomegalovirus Infections; Drug Adminis | 1992 |
Opportunistic intraocular infections in AIDS.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Child; Child, Preschool; Choroiditis; Cyto | 1992 |
[Cytomegalovirus retinitis in AIDS. Effectiveness and complications of long-term therapy].
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Humans; L | 1992 |
Uvula and oesophageal ulcerations with foscarnet.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Esophagus; Foscarnet; Huma | 1992 |
Combined and alternating ganciclovir/foscarnet in HIV-related cytomegalovirus encephalitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Infections; Foscarnet; Ganciclovir; Ho | 1992 |